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Over the last fifteen years, there have been substantial improvements in how we study the 
association between trait and genetic variations in the human genome. Genome-wide association 
studies (GWAS) now routinely test millions of variants in hundreds of thousands of individuals 
and the advance of genome sequencing technology allows us to examine the role of genetic 
variants across the full allele-frequency spectrum. However, with these changes come new 
challenges in analyzing and interpreting genetic results. In this dissertation, we present methods to 
aggregate sequence data and identify significant associations in common and rare variant analysis. 
In chapter two, we compare two strategies to aggregate sequence data from multiple studies: joint 
variant calling of all samples together versus calling each study individually and then combining 
the results using meta-analysis. Although joint calling is the gold standard, single-study calling 
can be more appealing due to fewer privacy restrictions and smaller computational burden. We 
use deep- and low-coverage sequence data on 2,250 samples from the GoT2D study to compare 
the two strategies in terms of variant detection sensitivity, genotype accuracy, and association 
power. We show single-study calling to be a viable alternative to joint calling for deep-coverage 
sequence data but show them to have noticeable discrepancies in rare variant calling and 
association results for low-coverage sequence data. 
In chapter three, we revisit the common variant P-value significance threshold of 5´10-8 and 
explore the rates of true and false discoveries that can be expected using less restrictive P-value 
thresholds and three other multiple testing procedures: Benjamini-Hochberg (BH) and Benjamini-
Yekutieli (BY) for controlling false discovery rate (FDR), and Bayesian false discovery probability 
for controlling Bayesian FDR. Using data from the Global Lipids and GIANT consortia, we show 
for large sample common variant GWAS that using a less stringent P-value threshold of 5´10-7 or 
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use of the BH procedure at target FDR threshold of 5% substantially increases the number of true 
positive discoveries while only modestly increasing false positive discoveries compared with the 
5´10-8 threshold. The latter threshold remains appropriate for modest-sized studies or for resource-
intensive follow-ups such as constructing animal models where a stringently curated list of 
significant loci is desired from GWAS. 
In the chapter four, we propose a Bayesian method for multiple testing correction in rare variant 
studies that calculates the posterior probabilities using an approximation of the Bayes factor and 
estimates prior parameters from summary statistics using an Expectation-Maximization algorithm. 
Using simulations analyses of ~400,000 individuals and ~107 million variants from the TOPMed-
imputed UK Biobank study, we show that our Bayesian method discovers more true positive loci 
than P-value-based methods such as the P-value threshold, BH, and BY procedures at equivalent 
false positive rates. In addition, we show that the Bayesian method controls empirical FDR among 
discovered loci. Finally, we estimate the genome-wide significant P-value threshold for testing 












1.1 From then to now 
We have come a long way in understanding our own genetic makeup. What started thirty years 
ago as an ambitious project to completely sequence a single human genome (International Human 
Genome Sequencing Consortium, 2001) has now evolved into efforts such as the UK Biobank 
(UKBB) and the Trans-Omics for Precision Medicine (TOPMed) programs that routinely sequence 
tens of thousands of individuals with unprecedented accuracy (Hout et al., 2019; Taliun et al., 
2019). The goal, however, remains the same: to use our understanding of the human genome to 
improve the lives of people worldwide. 
1.2 Understanding impact of genetic variations 
It is not enough to simply identify the DNA bases that constitute our genome, we need to 
understand how variations in the genome between individuals affect the incidence or severity of 
common diseases. This process was facilitated by the development of genome-wide association 
studies (GWAS) that test for links between millions of genetic variants and diseases or traits 
(Wellcome Trust Case Control Consortium, 2007). However, there are several challenges in 
GWAS ranging from issues in experimental design to difficulties in interpreting the results (M. I. 
McCarthy et al., 2008).  
1.3 Aggregating data from different studies 
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Genetic associations with complex diseases often have small effect size which makes it difficult 
to identify and replicate them in a single GWAS with limited power (Burton et al., 2009). A 
solution is to increase sample size by combining data from multiple genetic studies using meta-
analysis (Zeggini & Ioannidis, 2009). This method has been remarkably successful in increasing 
the number of discovered loci for diseases such as type 2 diabetes (Fuchsberger et al., 2016; Morris 
et al., 2012) and obesity (Yengo et al., 2018). 
With the remarkable improvement in sequencing technology, it has become possible for studies to 
conduct whole-genome sequencing of their samples. Just like array-based GWAS, individual 
sequencing studies face issues of small sample size that can be alleviated by aggregating sequence 
data across multiple studies. However, unlike array-based meta-analysis where participating 
cohorts typically perform genotype imputation (Y. Li et al., 2009a) on the same reference panel, 
sequencing is performed individually by each cohort, often using different technology platforms 
(Fox et al., 2014) and variant calling pipelines (Jun et al., 2015; McKenna et al., 2010). This raises 
the question of whether association results from meta-analysis of sequencing studies can achieve 
the same power as the gold standard joint analysis like it did for array-based meta-analysis (D. Y. 
Lin & Zeng, 2010). 
1.4 Correcting for multiple testing in GWAS 
Prior to GWAS, genetic association studies faced issues of irreproducibility in their reported 
discoveries (Hirschhorn et al., 2002) which could be partly attributed to a lax significance 
threshold that did not adequately account for the large testing burden explicitly or implicitly 
present in such studies (Risch & Merikangas, 1996). To address this, the genetics community 
adopted a stringent P-value threshold of 5×10-8 to define genome-wide significant associations by 
controlling the family-wise error rate at 5% based on the work of several groups (Dudbridge & 
Gusnanto, 2008a; Pe’er et al., 2008a). The success of this method in producing tens of thousands 
of largely reproducible results (Buniello et al., 2019) has likely limited interest in alternative 
multiple testing methods such as the Benjamini-Hochberg procedure (Benjamini & Hochberg, 
1995). Such methods based on the false discovery rate (FDR) have the potential to increase true 
positive discoveries at the cost of a theoretically controlled number of false positives. However, 
there are complications (Brzyski et al., 2017) with adapting FDR-controlling methods to GWAS, 
chief among them the need to account for the complex linkage-disequilibrium structures present 
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among the genetic variants included in genetic studies (The International HapMap Consortium, 
2007). 
1.5 More variants more problems 
The development of sequencing technology along with larger imputation reference panels such as 
those from the 1000 Genomes phase 3 study (The 1000 Genomes Project Consortium et al., 2015), 
Haplotype Reference Consortium (S. McCarthy et al., 2016), and TOPMed (Taliun et al., 2019) 
has allowed us to accurately identify and study low-frequency (minor allele frequency [MAF] 0.5-
5%) and rare variants (MAF < 0.5%). Exploring the full allele frequency spectrum can potentially 
explain a greater proportion of the genetic contribution to complex diseases (Seunggeung Lee et 
al., 2014) than common variants (MAF > 5%) alone and provide us with a better understanding of 
the genetic factors that influence disease risk and variability in quantitative traits. Of course, more 
variants in our association studies also means an increased testing burden that must be corrected 
for to properly control false positives (Pulit et al., 2017). Here, the relatively recent emergence of 
rare variant studies provides the opportunity to develop alternative multiple testing methods in a 
field where the P-value threshold is less clearly established. These methods include the 
aforementioned FDR-controlling procedures (Benjamini & Hochberg, 1995; Benjamini & 
Yekutieli, 2001a; Brzyski et al., 2017) as well as Bayesian approaches (Wakefield, 2007a; 
Whittemore, 2007) that use posterior probabilities instead of P-values. 
1.6 P-value versus Bayes factor and connection to multiple testing 
In GWAS, we typically use P-values to assess the evidence for association between tested variants 
and a trait of interest. Although a P-value is theoretically simple and well defined -- the probability 
of obtaining a result at least as extreme as what was observed under the assumption that the null 
hypothesis is true -- it is often misconstrued (Wasserstein & Lazar, 2016). A frequent 
misinterpretation is that P-values measure the probability of the null hypothesis given the data 
(Held & Ott, 2018) but such direct inferences can only be achieved using Bayes factors (BF) which 
is the ratio of likelihoods of the observed data under the null versus alternative hypotheses. Past 
works (Berger & Sellke, 1987; Sellke et al., 2001) have shown that P-values can be interpreted in 
a Bayesian manner through calibration using the function 𝐵(𝑝) = −e	𝑝log(𝑝). For P-values (𝑝) < 1/e, this function acts as a lower bound on the BF and can further be used to calculate the posterior 
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probability of the null hypothesis using the equation (1 + 𝐵(𝑝)!")!" under the assumption that 
the prior probability of the null hypothesis is equal to 1/2. 
For multiple testing in GWAS, P-value-based methods such as the P-value threshold or the 
Benjamini-Hochberg procedure are the easiest to use because most publicly available association 
results are presented in terms of P-values. Calculating the BF, and subsequently the posterior 
probability of the null hypothesis given the data, requires access to individual-level genotype data 
that may not be publicly shared due to privacy and other concerns (Paltoo et al., 2014). As an 
alternative, Johnson (2005) proposed to calculate the BF using the observed test statistics instead 
of the original data. Wakefield (2007a) proposed a version of this test-based BF for GWAS: 
𝐴𝐵𝐹(𝑍,𝑊) = 5𝑉 +𝑊𝑉 exp 9−𝑍#2 : 𝑊𝑉 +𝑊;< 
which can be calculated using just the test statistic (𝑍), testing variance (𝑉), and the prior variance 
(𝑊) of variant effect. Although this approximate BF (ABF) is calculated using the P-value (from 
the test statistic 𝑍), these two measures do not provide the same ranking of tested variants and thus 
will declare different sets of variants to be significantly associated with the trait. However, these 
two approaches can be reconciled using an alternative formulation of the ABF (Wakefield, 2009) 
that eliminates the prior and testing variance: 
𝐴𝐵𝐹(𝑍) = √1 + 𝐾 exp 9−𝑍#2 : 𝐾1 + 𝐾;< 
where 𝐾 = 𝑊/𝑉 and does not depend on the data. This version of the ABF only depends on the 
data through 𝑍# and produces the same ranking of tested variants as P-values.   
1.7 Overview 
In this dissertation, I develop statistical methods to address the challenges in analyzing and 
interpreting genetic results. A list of the datasets that used throughout this dissertation and their 
public availability is shown in Table 1.1. In Chapter 2, I present a protocol to aggregate sequence 
data from multiple studies considering sequence coverage and power of subsequent association 
analyses. In Chapter 3, I investigate the performance of less restrictive P-value thresholds and 
alternative multiple testing methods in common variant GWAS and present a procedure for 
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calculating their true and false positive rates in empirical studies by leveraging the sequential 
nature of meta-analyses. In Chapter 4, I propose a Bayesian method for multiple testing correction 
that increases true positive discovery in rare variant studies compared with the P-value threshold 
while still maintaining control of FDR. 
Table 1.1: Description of datasets 
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Meta-analysis of 
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Combining Sequence Data from Multiple Studies: Impact of 
Analysis Strategies on Rare Variant Calling and Association Results 
 
2.1 Introduction 
Genome-wide association studies (GWAS) based on genotype arrays have identified thousands of 
common (minor allele frequency [MAF] >5%) genetic variants associated with a wide range of 
human diseases and traits (Hindorff et al., 2012). However, these common variants comprise only 
10% of the ~84 million variant sites discovered in the human genome by the 1000 Genomes Project 
(The 1000 Genomes Project Consortium et al., 2015) with the rest being low-frequency (MAF 0.5-
5%; ~14%) and rare (MAF < 0.5%; ~76%) variants that are less well captured by genotype arrays 
and subsequent genotype imputation (Zuk et al., 2014). With the advance of genome sequencing 
technology, we can now directly study the role of variants across the full allele-frequency 
spectrum. Although sequencing studies to date have reaffirmed and expanded on the common 
variant associations of array-based GWAS, the modest sample sizes of most sequencing studies to 
date have limited the discovery of rare and low-frequency variant associations (Auer et al., 2016; 
Fuchsberger et al., 2016). 
To increase sample size, researchers often aggregate sequence data across multiple studies. To 
combine sequence data across studies, the gold standard strategy is to jointly call all samples 
together (Auer et al., 2016). This joint calling strategy increases the quality of variant calls and 
minimizes batch effects such as those due to different sequencing centers or platforms (Auer et al., 
2016). However, joint calling for sequence data can be difficult to implement due to restrictions 
on data sharing (Jiang et al., 2014; Paltoo et al., 2014) and the potentially heavy computation 
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burden (Exome Aggregation Consortium et al., 2016). An alternative strategy that adheres to 
privacy rules and mitigates computing load is single-study calling (Okada et al., 2018) which 
variants are identified and genotypes called separately within each study and then combined 
through meta-analysis of study-level association statistics or joint analysis of pooled individual-
level data (i.e. mega-analysis). Although single-study calling is easier to implement than the gold 
standard joint calling, there is a need to quantify the difference in calling results between these two 
strategies and assess how it affects downstream association analysis. 
Past research has shown that meta-analysis of study-level association results is as statistically 
efficient as joint analysis of individual-level data for combining common-variant GWAS (D. Y. 
Lin & Zeng, 2010). More recent research has extended methods for meta-analysis to sequencing 
studies for rare variants (Z.-Z. Tang & Lin, 2015). However, this research only analyzes the 
relative power of joint and meta-analysis under a single-study calling strategy and does not 
consider the impact of joint calling on association results. In addition, sequencing studies often 
differ in sequencing coverage depending on project needs and goals. For example, deep-coverage 
sequencing results in improved genotyping accuracy, particularly for rare variants (Seunggeung 
Lee et al., 2014; Chao Xu et al., 2017), while low-coverage sequencing results in more sequenced 
samples at the same cost (Y. Li et al., 2011). Thus, there is also a need to compare rare variant 
association tests for joint and single-study calling under different sequencing coverage. 
In this paper, we aim to quantify the difference between the gold standard joint calling and the 
alternative single-study calling strategies and assess their impact on association testing of rare 
single nucleotide variants (SNVs) in deep and low-coverage sequence data. Specifically, we 
compare variant detection and genotyping accuracy for joint and single-study callsets on deep-
coverage whole exome sequence (WES) and low-coverage whole genome sequence (WGS) 
dataset from the Genetics of Type 2 Diabetes (GoT2D) study (Fuchsberger et al., 2016) using the 
GotCloud variant calling pipelines (Jun et al., 2015) at default settings. Then for each data type, 
we compare single-variant and gene-based association test results for rare SNVs between three 
types of joint and single-study strategies: 1) joint calling with joint analysis, 2) single-study calling 




2.2.1 Data description 
We analyzed data on 2,250 individuals from the GoT2D study (Fuchsberger et al., 2016) for whom 
deep-coverage whole exome sequence (mean depth 82X), low-coverage whole genome sequence 
(mean depth 5X), and Illumina HumanOmni 2.5M array data were all available. Study participants 
came from five geographical regions: (1) Augsburg, Germany (n=193; KORA study), (2) the 
Botnia region of western Finland (n=303; DGI study), (3) Sweden (n=391; DGI study), (4) the 
United Kingdom (n=473; UKT2D study), and (5) Finland (n=890; FUSION study). For clarity, 
we will refer to the sample of 2,250 individuals as the “joint” cohort and the five subsets as the 
“single-study” cohorts (Figure 2.1). 
Figure 2.1: Workflow for variant calling and association analysis. 
 
Sequencing and alignment are described in Fuchsberger et al., 2016. Haplotype-based refinement was only 




2.2.2 DNA sample preparation and sequencing 
DNA samples were processed at the Broad Institute (FUSION and DGI), Wellcome Trust Centre 
for Human Genetics (UKT2D), and Helmholtz Zentrum München (KORA). DNA samples were 
genome and exome sequenced using the Illumina GAII or HiSeq 2000 sequencers. Sequence data 
were aligned to human reference genome version 19 (hg19) using Picard (DePristo et al., 2011) 
and BWA (H. Li & Durbin, 2009). Further details on data generation, processing, and quality 
control can be found in Fuchsberger et al. (2016). 
Processed and filtered sequence reads for the joint and single-study cohorts were analyzed by the 
GotCloud and GATK (McKenna et al., 2010; Van der Auwera et al., 2013) variant calling pipelines 
according to the best practice workflows recommended by their developers at default settings. We 
restricted our analyses to chromosome 2 (~8% of the human genome) to reduce computational 
burden. 
2.2.3 Whole-genome and exome sequence data processing: GotCloud and 
GATK pipeline 
We called SNVs with GotCloud at default settings using processed BAM files (Figure 2.1). We 
used SAMtools pileup and glfFlex to generate genotype likelihoods for all samples in 5 Mb 
chromosomal segments. We then used a support vector machine classifier to filter out likely false-
positive variant sites (Jun et al., 2015). 
Adhering to the recommended GATK workflow, we “hard called” every variable site in each 
sample for the number of non-reference alleles (0, 1, or 2) using HaplotypeCaller in GVCF mode. 
To parallelize this step, we divided chromosome 2 into 5 Mb segments with 100 bp overlap and 
simultaneously carried out hard-calls within each segment. We merged intermediate genomic VCF 
(gVCF) files from each sample into batches of 100 samples with CombineGVCFs and then jointly 
genotyped them with GenotypeGVCFs. We used the GATK CatVariants tool to concatenate 
variant sets from all genomic regions to form a combined callset. We identified a set of high-
quality variant calls from the raw variant callset using the Variant Quality Score Recalibration 
(VQSR) method which applies machine learning algorithms to score each variant call and filter 
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them at a desired level of sensitivity. We used GATK VariantRecalibrator and ApplyRecalibration 
to filter the raw variant callset at the recommended tranche threshold of 99.9% which provides 
high sensitivity while maintaining a reasonable level of specificity. Finally, we removed indels 
from the filtered variant callset in keeping with our settings for the GotCloud pipeline and to focus 
on SNVs in subsequent analyses.  
We used haplotype-based refinement to improve genotype and haplotype quality for whole 
genome genotype calls from both pipelines (Figure 2.1). Specifically, we used Beagle (Browning 
& Yu, 2009) to phase the genotype data in chunks of 10,000 SNVs with 1,000 SNVs overlaps and 
refined the phased sequences using Thunder (Jun et al., 2015) with 300 states.  
We ran whole exome sequence reads through the GotCloud and GATK discovery pipelines under 
the same settings as the whole-genome data. We did not apply any refinement steps to the exome 
calls, consistent with standard practice for both pipelines for deep-coverage sequence data. 
The final dataset for each of the four combinations of sequencing coverage (genome and exome) 
and pipeline (GotCloud and GATK) consists of a joint callset for all 2,250 samples, five separate 
single-study callsets for the geographically subdivided cohorts, and a union callset which merges 
the five single-study callsets. Since comparing the joint callset to five single-study callsets 
individually is difficult because detection of rare SNVs is heavily dependent on sample size and 
the results would be potentially skewed by the considerable sample size differences between 
cohorts, we use the union callset as an overall representation of single-study calling to provide a 
more apt comparison with the joint callset. For the union callset, we set genotype calls for SNVs 
not found in one or more of the single-study callset(s) as missing. 
2.2.4 Non-reference genotype accuracy 
For both pipelines, we assessed the accuracy of whole genome calls by comparing the Thunder-
refined non-reference genotypes against a set of 192,322 variants of highly accurate (“high-
confidence”) genotypes determined through joint statistical analysis of deep-coverage (~82X) 
exome sequence and Illumina HumanOmni 2.5 array data in the GoT2D whole genome sequencing 
study (Fuchsberger et al., 2016). We assessed the accuracy of exome calls by comparing unrefined 
non-reference genotypes against the set of high-confidence genotypes from Illumina HumanOmni 
2.5 array data. 
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2.2.5 Single-variant association analysis 
We evaluated the impact of joint and single-study calling on single-variant association tests by 
comparing -log10p-values from joint analysis of the joint callset against those from meta-analysis 
of single-study summary statistics and joint analysis of the union callset (i.e. mega-analysis). In 
each single-study callset, we used the logistic score test to test for T2D association under an 
additive genetic model with the top two principal components as covariates (Figure 2.1). For meta-
analysis, we combined summary-level results from the single-study callsets with fixed-effects 
sample-size weighted meta-analysis using METAL (Willer et al., 2010) and with trans-ethnic 
meta-analysis using MR-MEGA software (Mägi et al., 2017). 
2.2.6 Gene-based association analysis  
We used SKAT-O to test for association with multiple rare and low-frequency SNVs within coding 
regions of the genome. We prepared four lists of SNVs (“masks”) based on MAF and functional 
annotation. For the creation of the masks, we considered a SNV to have MAF < 1% if its MAF in 
every one of the single-study callsets is <1%. Mask 1 contained SNVs predicted to be protein-
truncating, Mask 2 included all SNVs from Mask 1 together with missense SNVs with MAF < 1%, 
Mask 3 included all SNVs from Mask 1 and those predicted to be deleterious by all five algorithms 
applied (Polyphen2-HumDiv, PolyPhen2-HumVar, LRT, Mutation Taster, and SIFT), and Mask 
4 included all SNVs from Mask 1 and those predicted to be deleterious by at least one algorithm 
with MAF < 1%. 
We performed SKAT-O (Seunggeun Lee et al., 2012) analysis on the four masks separately within 
each single-study callset (Figure 2.1). We combined SKAT-O results from each single-study 
callset using Meta-SKAT-O test in the MetaSKAT R package (Seunggeun Lee et al., 2013) once 
assuming homogeneous genetic effects across single-study cohorts and again assuming 
heterogeneous genetic effects. 
2.3 Results 
2.3.1 Overview 
We evaluated the utility of single-study calling as an alternative to the gold standard joint calling 
by comparing these methods in terms of variant detection, genotype accuracy, and impact on 
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power of association tests for different sequencing coverage. For our analysis (restricted to 
chromosome 2 due to computational burden), we focus on the gold standard joint callset, which 
are calls from analyzing all 2,250 samples together (the “joint” cohort), the five single-study 
callsets, which are calls from the five geographically subdivided cohorts (the “single-study” 
cohorts: Germany, Botnia, Sweden, UK, Finland), and the union callset, which pools calls from 
the five single-study callsets. There are 25,689 deep-coverage WES SNVs and 2,101,401 (15,344 
when restricted to coding regions) low-coverage WGS SNVs in the joint callset and 26,364 deep-
coverage WES SNVs and 2,249,181 (16,457) low-coverage WGS SNVs in the union callset. We 
present only GotCloud results as we found choice of software pipelines (GotCloud or GATK) to 
have no meaningful impact on variant calling and association results. 
2.3.2 Union callset 
The union callset pools calling results from the five single-study cohorts by merging their SNV 
calls. For SNV sites found in only a subset of the studies, we assign missing genotypes for studies 
in which the SNV site was not called. Using the union callset, we examine the overlap in variant 
detection between single-study cohorts. For deep-coverage data, 78% of all rare SNVs detected by 
single-study calling (i.e. those in the union callset) are “study specific” (Table 2.1), meaning they 
were found in only one of the single-study callsets and missing in all others, compared with 1.2% 
of low-frequency SNVs and 0.05% of common SNVs (Table 2.1). Conversely, only 2.3% of rare 
SNVs in the union callset are found in all five studies (Table 2.1) compared with 80% of low-
frequency and 99% of common SNVs (Table 2.1). Similar numbers are seen for low-coverage data 
(restricted to coding regions) (Table 2.1). Overall, there are three possible reasons for a missing 
SNV site in a study: 1) the SNV was monomorphic in the study sample; 2) the variant caller did 
not have confidence to declare the SNV site; or 3) the SNV site was identified but removed by 
quality control as likely false-positive. However, for single-study calling, we are unable to 
differentiate between the three types of missingness because of privacy restrictions for individual-




Table 2.1:  Overlap in variant detection for the union callset 
Data type Variants detected by only one study 
Variants detected 
by  
2 to 4 studies 
Variants detected 
by  
all 5 studies 
Deep-coverage 
Rare (MAF <0.5%) 
Low-frequency (MAF 0.5-5%) 













Low-coverage (coding regions) 
Rare (MAF <0.5%) 
Low-frequency (MAF 0.5-5%) 













Note. The union callset pools variant calling results from the five single-study cohorts. Numbers in table 
refers to SNVs from chromosome 2 in deep-coverage (~82X) exome sequence data and low-coverage 
(~5X) genome sequence data restricted to coding regions. 
 
 2.3.3 Variant detection: callset size 
We evaluated variant detection for joint and single-study strategies by comparing the joint and 
union callsets across a range of MAFs. For low-frequency and common SNVs in both deep-
coverage exome and low-coverage genome (restricted to coding regions) sequence data, there is 
almost complete overlap between the joint and union callsets (Figure 2.2C-F). However, for rare 
SNVs, there are noticeable discrepancies between the two callsets as described below. 
The overwhelming majority of rare SNVs detected in deep-coverage data are found in both the 
joint and union callsets (97% of all rare SNVs) with the remaining SNVs found exclusively in the 
joint (0.1%) and union (2.9%) callsets (Figure 2.2A). Contrary to expectations, the union callset is 
larger than the joint callset, mainly due to inconsistencies in variant filtering. Of the 631 rare SNVs 
exclusive to the union callset, 540 of them were filtered out during joint calling and excluded from 
the final joint callset. SNVs in joint calling go through variant filters once whereas SNVs in single-
study calling have one chance per study to pass filters and be included in the union callset. In this 
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scenario, a lack of consistent variant filtering between joint and single-study calling can lead to 
the differences seen here. 
For rare SNVs in low-coverage data (Figure 2.2B), we observed a similar pattern of variant 
detection as for deep-coverage data. However, inconsistencies in variant filtering only accounts 
for a small fraction of differences between the joint and union callsets. Only 128 of the 1,107 rare 
SNVs exclusive to the union callset were filtered out during joint calling. 
Figure 2.2: Comparison of variant detection between joint and single study calling strategies 
 
Comparison for rare (MAF<0.5%), low-frequency (MAF 0.5-5%), and common (MAF>5%) SNVs in deep-






2.3.4 Variant detection: genotype calls 
In addition to comparing the number of SNVs detected by joint and single-study calling, we also 
compared the genotype calls made by the two strategies at different sequencing coverage. We 
show in Tables 2.2 and 2.3 the comparison of genotype calls between joint and the single-study 
calling for 9,096 rare SNVs found in the joint and union callsets from deep-coverage exome as 
well as from low-coverage genome (restricted to coding regions) sequence data. Genotype 
comparisons for 2,127 low-frequency and 2,027 common SNVs are shown in Supplementary 
Tables 2.1-2.4. Excluding missing calls, overall genotype discordance between joint and single-
study calling is lower in deep-coverage data than in low-coverage data. Furthermore, for rare 
SNVs, 64% of all genotype calls from single-study calling in deep-coverage data (Table 2.2) are 
missing compared with 70% for low-coverage data (Table 2.3). Breaking down rare SNVs further 
by minor allele count (MAC), we observe this missingness to be a function of MAC in both types 
of sequencing data with the rarest categories most affected. In deep-coverage data, we can attribute 
almost all missing calls for rare SNVs to monomorphic SNVs in the single-study cohort(s) since 
13,093,060 of the 13,093,128 missing single-study calls were called as homozygous reference by 
joint calling (Table 2.2). Using the GATK pipeline, it is possible to identify monomorphic SNVs 
in gVCFs and assign homozygous reference genotypes to the 13,093,060 missing calls. However, 
we were unable to do this for the GotCloud pipeline since it does not support gVCFs. In low-
coverage data, 6,365 of 14,246,613 missing single-study calls were called as non-reference by 
joint calling (Table 2.3) compared with 68 non-reference calls for deep-coverage data (Table 2.2). 
Since rare SNVs naturally have low allele counts to begin with, any small change to their overall 
allele counts will have a noticeable impact on association testing and other downstream analyses. 
Finally, the missingness appears to be mostly localized to rare SNVs as we observe only a slight 
number of missing genotype calls in low-frequency SNVs (4.3% in deep-coverage data, 9.2% in 
low-coverage data; Supplementary Tables 2.1 and 2.2) and a negligible number in common SNVs 









Joint variant calling (joint callset) 
Missing Homozygous reference Heterozygous 
Homozygous 
alternate Total 
Missing 0 13,093,060 (64%) 68 (0.00033%) 0 13,093,128 (64%) 
Hom. ref. 0 7,135,459 (35%) 9 (0.000044%) 0 7,135,468 (35%) 
Heterozygous 0 31 (0.00015%) 25,862 (0.13%) 0 25,893 (0.13%) 
Hom. alt. 0 0 4 (0.000020%) 211,507 (1.0%) 211,511 (1.0%) 
Total 0 20,228,550 (99%) 25,943 (0.13%) 211,507 (1.0%) 20,466,000 (100%) 
Note. Genotype calls from joint (horizontal axis) and single-study (vertical axis) calling strategies for 
9,096 rare (MAF <0.5%) SNVs from chromosome 2 in deep-coverage (~82X) exome sequence data. 
Concordant calls between the two strategies are highlighted in bold. 
 
Table 2.3: Comparison of genotype calls for rare SNVs from low-coverage genome sequence 




Joint variant calling (joint callset) 
Missing Homozygous reference Heterozygous 
Homozygous 
alternate Total 
Missing 0 14,240,248 (70%) 5,966 (0.029%) 399 (0.002%) 14,246,613 (70%) 
Hom. ref. 0 5,981,638 (29%) 1,855 (0.009%) 2 (0.000010%) 5,983,495 (29%) 
Heterozygous 0 3,687 (0.02%) 21,073 (0.10%) 99 (0.00048%) 24,859 (0.12%) 
Hom. alt. 0 0 37 (0.00018%) 210,996 (1.0%) 211,033 (1.0%) 
Total 0 20,225,573 (99%) 28,931 (0.14%) 211,496 (1.0%) 20,466,000 (100%) 
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Note. Genotype calls from joint (horizontal axis) and single-study (vertical axis) calling strategies for 9,096 
rare (MAF <0.5%) SNVs from chromosome 2 in low-coverage (~5X) genome sequence data restricted to 
coding regions. Concordant calls between the two strategies are highlighted in bold. 
 2.3.5 Genotype concordance 
We assessed non-reference genotype accuracy (hereafter referred to as “genotype concordance”) 
of joint and single-study calling in deep-coverage exome sequence data by comparing non-
reference calls for SNVs found in both the joint and union callsets against a “truth” set of high 
confidence genotypes from Illumina HumanOmni 2.5 array data (Fuchsberger et al., 2016). The 
joint and union callsets have nearly identical genotype concordance with the truth set for SNVs of 
all MAFs and negligible differences in raw counts (Table 2.4). 
Next, we assessed genotype concordance for SNVs in low-coverage genome sequence data (not 
restricted to coding regions to preserve a meaningful number of comparisons) by comparing 
against high confidence genotypes from Illumina HumanOmni 2.5 array data and/or from deep 
(~82X) exome sequence in the GoT2D integrated panel (Fuchsberger et al., 2016). The joint callset 
correctly calls 0.4% more genotypes than the union callset for rare SNVs, 0.5% more for low-
frequency SNVs, and 0.2% more for common SNVs (Table 2.4). Compared with deep-coverage 
data, here we observe a larger difference in genotype concordance with the truth set between the 
joint and union callsets. For example, the joint callset calls 13,322 more genotypes correctly (out 
of 3,575,402 total comparisons) than the union callset for rare SNVs in low-coverage data while 
it only calls 1 more genotype correctly (out of 91,756) for rare SNVs in deep-coverage data. As 
expected, the improvements to calling accuracy offered by larger sample sizes in the joint strategy 




Table 2.4: Non-reference genotype accuracy for joint and single-study calling strategies 
Data type Genotype concordance for joint callset 
Genotype concordance 
for union callset 
Deep-coverage 
Rare (MAF <0.5%) 
Low-frequency (MAF 0.5-5%) 









Low-coverage (all regions) 
Rare (MAF <0.5%) 
Low-frequency (MAF 0.5-5%) 









Note. Genotype concordance for joint and single-study calling strategies in deep-coverage (~82X) exome 
and low-coverage (~5X) genome sequence data. The “truth” set of high confidence genotypes being 
compared against comes from Illumina HumanOmni 2.5 array data and deep exome sequence in the 
GoT2D integrated panel. Raw genotype counts are displayed in parentheses. 
  
2.3.6 Effect of GC bias on genotype concordance 
It is a well-known that sequencing read coverage tends to be lower in high GC-content regions. To 
investigate the effect of this GC bias on joint and single-study calling, we compared genotype 
concordance between the joint and union callset in regions of low GC-content (<60% of base pairs 
are GC) and in regions of high GC-content (≥60%) in chromosome 2. In low GC-content regions, 
we observe similar genotype concordance between the joint and union callset in both deep- and 
low-coverage sequence data (Supplementary Table 2.5). In high GC-content regions, we observe 
similar genotype concordance between the two callsets in deep-coverage data but notice larger 
differences in low-coverage data where the joint callset correctly calls 0.7% more genotypes than 
the union callset for rare and low-frequency SNVs (Supplementary Table 2.6). The performance 
of the two calling strategies in high GC-content regions are nearly equal in deep-coverage data but 
single-study calling can be slightly less accurate than joint calling in low-coverage data. 
2.3.7 Association analysis 
Overall, we observe similar p-values between joint analysis of the joint callset, fixed-effects meta-
analysis of single-study summary statistics, and joint analysis of the union callset (mega-analysis) 
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for rare SNVs in deep-coverage data (Figure 2.3A-C). This is due to almost perfect concordance 
in genotype calls between joint and single-study calling and the fact that missing variant calls for 
rare SNVs from single-study calling were almost all called as homozygous reference in the joint 
callset. However, for low-coverage data, we observe large discrepancies in p-values between joint 
and meta-analysis (Figure 2.3D) as well as between joint and mega-analysis for rare SNVs (Figure 
2.3E). These differences in association results is caused by a combination of lower concordance 
in genotype calls between the two calling strategies for low-coverage data and an increase in the 
number of missing single-study calls being called as non-reference in the joint callset. Since both 
meta-analysis and mega-analysis use single-study calling, their association results are more similar 
(Figure 2.3F). 
Figure 2.3: Comparison of single-variant association test p-values between joint and single 
study calling strategies for rare SNVs 
 
Comparison for rare (MAF<0.5%) SNVs in (A-C) deep-coverage (~82X) exome sequence data and (D-F) 
low-coverage (~5X) genome sequence data. Joint refers to joint analysis of the joint callset, meta refers to 
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meta-analysis of single-study summary statistics, and mega refers to joint analysis of the union callset 
(mega-analysis). 
 
We evaluated association power between joint and single-study calling for gene-based tests by 
comparing -log10p-values from SKAT-O test of the joint callset versus those from meta-analysis 
of single-study SKAT-O test results assuming homogeneous genetic effects. For all masks, SKAT-
O based joint analysis and Meta-SKAT-O based meta-analysis produce similar p-values 
(Supplementary Figure 2.3). 
2.3.8 Heterogeneity between single-study cohorts 
To address possible heterogeneity in genetic effects between our single-study cohorts, we 
combined single-study summary statistics using a trans-ethnic meta-analysis implemented in MR-
MEGA and combined single-study SKAT-O test results using Meta-SKAT-O assuming 
heterogeneous genetic effects. For single-variant tests, we observe that trans-ethnic meta-analysis 
had slightly greater power to detect variants whose heterogeneity in genetic effects were correlated 
with ancestry compared with fixed-effects meta-analysis (Supplementary Figure 2.4). However, 
none of these variants are close to reaching genome-wide significance (p-value<5x10-8) while 
those that are have more significant p-values under a fixed-effects meta-analysis. For gene-based 
tests, we observe slight variations in p-values between homogeneous and heterogeneous effect 
meta-analyses for Masks 1 and 3 but much greater p-value variability for Masks 2 and 4 
(Supplementary Figure 2.5). 
2.4 Discussion 
Although jointly calling all samples together is the gold standard strategy for analyzing rare SNVs 
in sequencing studies, single-study calling is more appealing due to fewer privacy restrictions and 
smaller computation burden. In this study, we compared joint and single-study calling in terms of 
variant detection, non-reference genotype concordance, and their impact on association power as 
a function of sequencing coverage. 
For single-study calling, we found that low overlap in variant detection among single-study cohorts 
for rare SNVs results in an abundance of “missing” genotype calls where we lose information for 
variant sites in cohorts where they were not detected. We show that for deep-coverage data, the 
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impact of missing genotype calls on association testing of rare SNVs from single-study calling is 
minimal because almost all of this missingness is due to monomorphic SNVs, as evident by 
corresponding homozygous reference calls in the joint callset. However, for low-coverage data, 
average read depth is low and thus, a portion of the missing genotype calls may be due to lack of 
coverage at the variant sites (Xu et al., 2017). Indeed, we show that a fraction amount of missing 
single-study calls for rare SNVs in low-coverage data have corresponding non-reference calls in 
the joint callset, resulting in lower than expected allele counts and reduced power for association 
testing of these SNVs. In addition, these missing calls can have a negative impact on gene-based 
aggregation tests, which will be underpowered if too many variant sites within a gene have missing 
genotype calls, and genotype-based callbacks, since the majority of loss-of-function SNVs are 
rare. A possible, but resource-intensive solution is to generate a list of SNV sites based on the 
union callset and then go back and genotype these sites within each single-study cohort. With 
parallel computation for each sample and every 5 Mb chromosomal segment, this process takes on 
average one hour CPU-time per sample per cohort with a maximum memory usage of 
approximately 0.5 GB to re-call 1 to 1.2 million variants in chromosome 2. 
Although the low overlap in variant detection among single-study cohorts for rare SNVs can arise 
naturally due to sample population differences between cohorts, another contributing factor is the 
inconsistency of variant calling filters (i.e. false-positive screening). In our analysis, rare SNVs 
that were filtered out during joint calling may pass filters during calling in some single-study 
cohorts while being filtered out in others. This increases the possibility of introducing false-
positive SNVs to downstream analyses since they only need to pass filters in one of the single-
study cohorts to be included in association tests. 
2.4.1 Recommendations 
For deep-coverage data, single-study calling and either meta-analysis or mega-analysis can be 
recommended as a viable alternative to joint calling and analysis for rare SNVs based on almost 
perfect concordance of genotype calls between the two calling strategies, comparable non-
reference genotype concordance with an external truth set, and comparable association results. 
Furthermore, missing genotype calls in single-study calling for deep-coverage data can be assumed 
to be homozygous reference and attributed to monomorphic variant due to a matching homozygous 
reference call for their counterparts in the joint callset. When combining many smaller single 
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studies, meta-analysis can be more conservative and less powerful than mega-analysis (Ma et al., 
2013). 
For low-coverage data or low-coverage regions in deep data, single-study calling cannot be 
recommended as a viable alternative to joint calling for rare SNVs. Discordance in genotype calls 
between the two calling strategies is approximately 150 times higher than that in deep-coverage 
data (0.09% versus 0.0006%) and combined with a sizable number of genotype calls in single-
study calling being missing due to lack of coverage at variant sites, we observe large discrepancies 
in association results between the two calling strategies. 
In general, for studying low-frequency and common SNVs, single-study calling can be used as an 
alternative to joint calling in both deep-coverage and low-coverage data (Supplementary Figures 
2.1 and 2.2). The only exception is for studying low-frequency SNVs in low-coverage data 
(Supplementary Figure 2.1D-F) where there remain noticeable discrepancies in association results 
between joint and meta/mega-analysis, although less than that seen for rare SNVs in low-coverage 
data. 
2.4.2 Comparison with GATK pipeline 
In addition to the GotCloud pipeline, we ran our analyses with the widely used GATK pipeline at 
default settings. Choice of software pipeline had a limited impact on variant detection and 
genotype accuracy (Supplementary Table 2.7) with little to no impact on association results (data 
not shown). There is more overlap in detected SNVs between joint and single-study calling for the 
GotCloud pipeline in deep-coverage data and vice versa for the GATK pipeline in low-coverage 
data. The GotCloud pipeline was slightly more accurate in calling common and low-frequency 
SNVs; however, on average this difference amounts to less than 1.5% more correctly called non-
reference genotypes.  
2.4.3 Summary 
We show single-study calling to be a viable alternative to joint calling for deep-coverage sequence 
data but show them to have noticeable discrepancies in rare variant calling and association results 




2.5 Supplementary figures 
 
Supplementary Figure 2.1: Comparison of single-variant association test p-values between 
joint and single study calling strategies for low-frequency SNVs 
 
Comparison for low-frequency (MAF 0.5-5%) SNVs in (A-C) deep-coverage (~82X) exome sequence 
data and (D-F) low-coverage (~5X) genome sequence data. Joint refers to joint analysis of the joint 
callset, meta refers to meta-analysis of single-study summary statistics, and mega refers to joint analysis 




Supplementary Figure 2.2: Comparison of single-variant association test p-values between 
joint and single study calling strategies for common SNVs 
 
Comparison for common (MAF >5%) SNVs in (A-C) deep-coverage (~82X) exome sequence data and 
(D-F) low-coverage (~5X) genome sequence data. Joint refers to joint analysis of the joint callset, meta 





Supplementary Figure 2.3: Comparison of gene-based association test p-values between joint 
and single study calling strategies in deep-coverage exome sequence data 
 
Mask 1: protein-truncating SNVs; Mask 2: Mask1+missense SNVs with MAF<1%; Mask 3: 
Mask1+SNVs predicted deleterious by all algorithms (Polyphen2-HumDiv, PolyPhen2-HumVar, LRT, 





Supplementary Figure 2.4: Comparison of trans-ethnic meta-analysis and fixed effects meta-
analysis 
 
Comparison of trans-ethnic meta-analysis (Het-Meta) using MR-MEGA and fixed effects meta-analysis 
(Hom-Meta) using METAL for (A) deep-coverage (~82X) exome sequence data and (B) low-coverage 
(~5X) genome sequence data. Red points denote variants whose heterogeneity in genetic effects is 
correlated with ancestry (p-value<0.05) while blue points denote variants whose heterogeneity is not 




Supplementary Figure 2.5: Comparison between gene-based meta-analysis assuming 
homogenous genetic effects between single-study cohorts versus heterogenous genetic effects in 
deep-coverage exome sequence data 
 
Comparison between gene-based meta-analysis assuming homogenous genetic effects between single-
study cohorts (Hom-Meta-SKAT-O) and gene-based meta-analysis assuming heterogenous genetic effects 
(Het-Meta-SKAT-O) in deep-coverage (~82X) exome sequence data. Mask 1: protein-truncating SNVs; 
Mask 2: Mask1+missense SNVs with MAF<1%; Mask 3: Mask1+SNVs predicted deleterious by all 
algorithms (Polyphen2-HumDiv, PolyPhen2-HumVar, LRT, Mutation Taster, and SIFT); Mask 4: 




2.6 Supplementary Tables 
 
Supplementary Table 2.1: Comparison of genotype calls for low-frequency SNVs from deep-




Joint variant calling (joint callset) 
Missing Homozygous reference Heterozygous 
Homozygous 
alternate Total 
Missing 0 205,517 (4.3%) 241 (0.005%) 1 (<0.000%) 205,759 (4.3%) 
Hom. ref. 0 4,292,576 (90%) 145 (0.003%) 0 4,292,721 (90%) 
Heterozygous 0 134 (0.003%) 168,488 (3.5%) 6 (<0.000%) 168,628 (3.5%) 
Hom. alt. 0 1 (<0.000%) 8 (<0.000%) 118,633 (2.5%) 118,642 (2.5%) 
Total 0 4,498,228 (94%) 168,882 (3.5%) 118,640 (2.5%) 4,785,750 (100%) 
Note. Genotype calls from joint (horizontal axis) and single-study (vertical axis) calling strategies for 
2,127 low-frequency (MAF 0.5-5%) SNVs from chromosome 2 in deep-coverage (~82X) exome 
sequence data. Concordant calls between the two strategies are highlighted in bold.   
 
Supplementary Table 2.2: Comparison of genotype calls for low-frequency SNVs from low-




Joint variant calling (joint callset) 
Missing Homozygous reference Heterozygous 
Homozygous 
alternate Total 
Missing 0 435,208 (9.1%) 4,551 (0.095%) 460 (0.010%) 440,219 (9.2%) 
Hom. ref. 0 4,051,957 (85%) 3,976 (0.083%) 20 (<0.000%) 4,055,953 (85%) 
Heterozygous 0 6,244 (0.13%) 164,676 (3.4%) 446 (0.009%) 171,366 (3.5%) 
Hom. alt. 0 35 (<0.000%) 348 (0.007%) 117,829 (2.5%) 118,212 (2.5%) 
Total 0 4,493,444 (94%) 173,551 (3.5%) 118,755 (2.5%) 4,785,750 (100%) 
Note. Genotype calls from joint (horizontal axis) and single-study (vertical axis) calling strategies for 
2,127 low-frequency (MAF 0.5-5%) SNVs from chromosome 2 in low-coverage (~5X) exome sequence 
data. Concordant calls between the two strategies are highlighted in bold. 
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Supplementary Table 2.3: Comparison of genotype calls for common SNVs from deep-




Joint variant calling (joint callset) 
Missing Homozygous reference Heterozygous 
Homozygous 
alternate Total 
Missing 0 5,418 (0.12%) 2,216 (0.049%) 1,876 (0.041%) 9,510 (0.21%) 
Hom. ref. 0 2,344,309 (51%) 913 (0.020%) 62 (0.001%) 2,345,284 (51%) 
Heterozygous 0 2,288 (0.050%) 1,454,893 (32%) 817 (0.018%) 1,457,998 (32%) 
Hom. alt. 0 34 (<0.000%) 930 (0.020%) 746,994 (16%) 747,958 (16%) 
Total 0 2,352,049 (51%) 1,458,952 (32%) 749,749 (16%) 4,560,750 (100%) 
Note. Genotype calls from joint (horizontal axis) and single-study (vertical axis) calling strategies for 
2,027 common (MAF >5%) SNVs from chromosome 2 in deep-coverage (~82X) exome sequence data. 
Concordant calls between the two strategies are highlighted in bold. 
 
Supplementary Table 2.4: Comparison of genotype calls for common SNVs from low-coverage 




Joint variant calling (joint callset) 
Missing Homozygous reference Heterozygous 
Homozygous 
alternate Total 
Missing 0 18,544 (0.41%) 12,430 (0.27%) 4,791 (0.11%) 35,765 (0.78%) 
Hom. ref. 0 2,318,025 (51%) 6,935 (0.15%) 104 (0.0023%) 2,325,064 (51%) 
Heterozygous 0 7,321 (0.26%) 1,443,179 (32%) 4,258 (0.093%) 1,454,758 (32%) 
Hom. alt. 0 105 (0.002%) 4,340 (0.095%) 740,718 (16%) 745,163 (16%) 
Total 0 2,343,995 (52%) 1,466,884 (32%) 749,871 (16%) 4,560,750 (100%) 
Note. Genotype calls from joint (horizontal axis) and single-study (vertical axis) calling strategies for 2,027 
common (MAF >5%) SNVs from chromosome 2 in low-coverage (~5X) exome sequence data. Concordant 






Supplementary Table 2.5: Non-reference genotype accuracy for joint and single-study calling 
strategies in low GC-content regions 
Data type Genotype concordance for joint callset 
Genotype concordance 
for union callset 
Deep-coverage 
Rare (MAF <0.5%) 
Low-frequency (MAF 0.5-5%) 









Low-coverage (all regions) 
Rare (MAF <0.5%) 
Low-frequency (MAF 0.5-5%) 









Note. Low GC-content regions denote regions of chr2 with <60% of base pairs as GC in data downloaded 
from UCSC Genome Browser (http://hgdownload.cse.ucsc.edu/downloads.html). Genotype concordance 
is for joint and single-study calling strategies in deep-coverage (~82X) exome and low-coverage (~5X) 
genome sequence data. The “truth” set of high confidence genotypes being compared against comes from 
Illumina HumanOmni 2.5 array data and deep exome sequence in the GoT2D integrated panel. Raw 
genotype counts are displayed in parentheses.   
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Supplementary Table 2.6: Non-reference genotype accuracy for joint and single-study calling 
strategies in high GC-content regions 
Data type Genotype concordance for joint callset 
Genotype concordance 
for union callset 
Deep-coverage 
Rare (MAF <0.5%) 
Low-frequency (MAF 0.5-5%) 









Low-coverage (all regions) 
Rare (MAF <0.5%) 
Low-frequency (MAF 0.5-5%) 









Note. High GC-content regions denote regions of chr2 with ≥60% of base pairs as GC in data downloaded 
from UCSC Genome Browser (http://hgdownload.cse.ucsc.edu/downloads.html). Genotype concordance 
is for joint and single-study calling strategies in deep-coverage (~82X) exome and low-coverage (~5X) 
genome sequence data. The “truth” set of high confidence genotypes being compared against comes from 
Illumina HumanOmni 2.5 array data and deep exome sequence in the GoT2D integrated panel. Raw 
genotype counts are displayed in parentheses.   
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Supplementary Table 2.7: Non-reference genotype accuracy for joint and single-study calling 
strategies using the GATK pipeline 
Data type Genotype concordance for joint callset 
Genotype concordance 
for union callset 
Deep-coverage 
Rare (MAF <0.5%) 
Low-frequency (MAF 0.5-5%) 









Low-coverage (all regions) 
Rare (MAF <0.5%) 
Low-frequency (MAF 0.5-5%) 









Note. Genotype concordance for joint and single-study calling strategies in deep-coverage (~82X) exome 
and low-coverage (~5X) genome sequence data. The “truth” set of high confidence genotypes being 
compared against comes from Illumina HumanOmni 2.5 array data and deep exome sequence in the 
















There has been recent discussion in the statistical community on changing the standard P-value 
significance threshold for a single test from 0.05 to 0.005 (Amrhein et al., 2019; Benjamin et al., 
2018; Wasserstein et al., 2019). Although the authors of the corresponding paper (Benjamin et al., 
2018) commended human geneticists for using very stringent P-value thresholds to help ensure 
reproducibility, the cost of this strategy in current genetic studies is that many true genetic signals 
are not identified. The benefit is, of course, rigorous control of false positives. 
To account for multiple testing in genome-wide association studies (GWAS), a fixed P-value 
threshold of 5´10-8 is widely used to identify association between a common genetic variant and 
a trait of interest. Risch and Merikangas (1996) suggested this strict P-value threshold for studying 
the genetics of complex diseases due to the many false positive discoveries reported by candidate 
gene studies at that time. Later, the International HapMap Consortium (Altshuler et al., 2005), 
Dudbridge and Gusnanto (Dudbridge & Gusnanto, 2008b), and Pe’er et al. (Pe’er et al., 2008b) 
independently suggested near-identical thresholds for common variant (minor allele frequency 
[MAF] > 5%) GWAS. Each group of investigators sought to control the family-wise error rate 
(FWER) through Bonferroni correction for the effective number of independent tests given the 
linkage disequilibrium (LD) structure of the genome; they used different approaches to estimate 
the effective number of independent tests. Based on these studies and reinforced by widespread 
use, the P = 5´10-8 threshold soon became standard for common variant GWAS. Using this 
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threshold has been remarkably successful in limiting false positive association findings, leading to 
robust and reproducible results in a field that prior to GWAS had reported many nonreplicable 
results. 
Since the acceptance of the P = 5´10-8 threshold a decade ago, there have been substantial 
experimental and methodological advances that have allowed study of many more common 
variants in much larger samples. The construction of denser genotype arrays (Burdick et al., 2006), 
development of genotype imputation (Y. Li et al., 2009b, 2010), and increasing sizes of imputation 
reference panels (S. McCarthy et al., 2016) now allow assay of nearly all common human genetic 
variants. Development of tools for meta-analysis (Willer et al., 2010; Winkler et al., 2014) has 
facilitated the aggregation of results across GWAS and contributed to the increasing sample sizes 
of genetic studies. With this changing landscape, it is worthwhile to revisit (Panagiotou et al., 
2012) the common variant genome-wide threshold of P = 5´10-8 considering the knowledge and 
data acquired in the last decade. 
Instead of controlling the FWER, an inherently conservative metric, an alternative approach to 
multiple testing corrections is to use adjusted P-values to control the false discovery rate (FDR) or 
to use posterior probabilities to control the Bayesian FDR (Efron et al., 2001). Although using the 
Benjamini-Hochberg (B-H) procedure (Benjamini & Hochberg, 1995) is the standard practice in 
expression quantitative trait locus (eQTL) studies and a Bayesian counterpart has also been 
proposed (Wen, 2017), FDR-controlling procedures have not been widely used in GWAS. In the 
case of B-H, this may be due to concerns about inflated estimates of FDR under the LD structure 
observed in genetic data (Schwartzman & Lin, 2011). Recently, Brzyski et al. (Brzyski et al., 2017) 
proposed a blocking strategy that groups tested variants into clusters based on LD before applying 
B-H and showed that this adapted procedure controlled the FDR at their target threshold of 5%. 
However, their analysis was limited to 364,590 variants in 5,402 samples and it is unclear how 
their procedure applies to meta-analysis where LD structures can vary across studies. There is a 
need to evaluate this adapted B-H and the more conservative Benjamini-Yekutieli (B-Y) procedure 
(Benjamini & Yekutieli, 2001b) as well as other procedures that control the Bayesian FDR over a 
broad range of FDR thresholds at the current scale of common variant GWAS with larger samples 
and millions of variants.   
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Here, we use knowledge gathered from current studies to re-evaluate earlier common variant 
GWAS meta-analyses and assess the impact of different multiple testing procedures on true and 
false positive rate. Along with varying the P-value threshold which controls the FWER, we 
evaluate the B-H and B-Y procedures to control the FDR, and the Bayesian false discovery 
probability (BFDP) procedure to control the Bayesian FDR. We apply the multiple testing 
procedures to earlier common variant meta-analyses from the Global Lipids (GLGC) and GIANT 
GWAS consortia on several frequently studied traits: lipid levels, height, and body mass index 
(BMI). Since the true set of causal variants for each trait is unknown, we use the latest and largest 
meta-analyses for each trait as the approximate “truth” to evaluate the performance of the multiple 
testing procedures in our empirical datasets. We supplement this analysis with simulation studies 
where the truth is known. Our results demonstrate that the standard 5´10-8 P-value threshold is the 
best multiple testing procedure for limiting false positives and is appropriate for modest-sized 
studies or for resource-intensive follow-ups such as constructing animal models where the cost of 
follow-up for each locus is high. In contrast, a less stringent P-value threshold of 5´10-7 (as first 
suggested by the Wellcome Trust Case Control Consortium (Wellcome Trust Case Control 
Consortium, 2007)) or the adapted B-H procedure at target FDR thresholds of 5% increases power 
to detect true positives  in large studies and can be viable for follow-ups where the cost of including 
a modestly greater set of false positives is low, such as gene set enrichment, pathway analysis, or 
high-throughput functional follow-ups. This in-depth examination provides useful guidance to 
investigators who are currently conducting GWAS. 
3.2 Methods 
3.2.1 Introduction 
We first consider an additive genetic model for a single continuous trait Y and the genotype Gj at 
variant 𝑗 = 1,… ,𝑚 
  𝑌 = 𝑋$𝛽 + 𝐺%𝜃% + 𝜀% ( 1 ) 
where X is a p ´ 1 vector of covariates including the intercept, b is a p ´ 1 vector of covariate 
effects, qj is the effect of variant j, and ej is the normally distributed error with mean 0 and variance 
s2j. This model can easily be extended to binary traits using a logit link function. 
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In a sample of n individuals, we wish to test the null hypotheses 𝐻&,%: 𝜃% = 0 against the alternatives 𝐻",%: 𝜃% ≠ 0 for each variant j. Table 3.1 summarizes the possible outcomes for the m tests of which 
m0 null hypotheses are true. For studying multiple testing procedures, we focus on the first row of 
the table: R is the total number of rejected null hypotheses, V the number of null hypotheses 
incorrectly rejected (false positives), and S the number of null hypotheses correctly rejected (true 
positives). The proportion of false positives Q among all rejected hypotheses is then equal to V/R 
for R > 0 and set to 0 for R = 0.  
Several procedures can be used to address the issue of controlling false positives when testing 
multiple hypotheses. In the remainder of this section we describe four such procedures, their 
extension to joint analysis of multiple traits, and application and assessment of these procedures 
in empirical and simulation studies in the context of common variant GWAS. 
Table 3.1: Outcomes for testing multiple hypotheses  
  True hypothesis Total 
  H0 H1  
Test 
H0 rejected V S R 
H0 not rejected U T m-R 
Total  m0 m-m0 m 
 
 
3.2.2 FWER control 
The standard procedure to correct for multiple testing in GWAS is to control the FWER, the 
probability of rejecting at least one true null hypothesis: 𝐹𝑊𝐸𝑅 = P(𝑉 > 0) = P(𝑄 > 0)	 
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Fixed P-value thresholds often control the FWER by using the Bonferroni procedure which 
provides control of FWER at level α by rejecting any null hypothesis 𝐻&,% for variant 𝑗 = 1,… ,𝑚 
with P-value 
𝑝% ≤ 𝛼𝑚	
When the variants are in LD and the corresponding test statistics are correlated, this procedure is 
conservative. One can increase the power of the Bonferroni procedure by adjusting for the effective 
number of independent tests (Altshuler et al., 2005; Dudbridge & Gusnanto, 2008b; Pe’er et al., 
2008b) m¢ £ m that takes into account LD.  
3.2.3 FDR control 
While FWER procedures control the probability of incorrectly rejecting at least one true null 
hypothesis, FDR procedures control the expected proportion of incorrectly rejected true null 
hypotheses. At equivalent values of α, FDR is a less conservative error rate than FWER (Goeman 
& Solari, 2014). In the context of Table 3.1, 
𝐹𝐷𝑅	 = 	𝐸[𝑄] 	= 	 V𝐸 W𝑉𝑅X 									𝑖𝑓	𝑅 > 0	0																𝑖𝑓	𝑅 = 0 
The Benjamini-Yekutieli (B-Y) procedure controls the FDR at level 𝛼 under any dependency 
structure by ordering the P-values for the m variants from smallest to largest: 𝑝("), … , 𝑝(*) and 
rejecting all null hypotheses 𝐻&,%, 𝑗 = 1,… , 𝑘 where k is the largest value for which 
𝑝(+) ≤ 𝑘𝑚: 𝛼𝑐(𝑚); 
and 
𝑐(𝑚) = ] 1𝑖*,	.	"  
The Benjamini-Hochberg (B-H) procedure, a commonly used FDR procedure that is valid when 




Applying the B-H or B-Y procedure to GWAS can be challenging because discoveries are counted 
in units of loci (clusters of nearby variants that are correlated due to LD) rather than by each 
individual variant. Thus, FDR-controlling procedures need to control for a subset of tested 
variants, typically the most strongly associated (lead) variant at each locus. Since FDR-control 
does not extend to a subset of the rejected null hypotheses (Goeman & Solari, 2014), we adapt the 
B-H and B-Y procedures to GWAS by applying an approach similar to that proposed by Brzyski 
et al. (Brzyski et al., 2017) We first cluster the m null hypotheses into m* < m loci by performing 
LD clumping on the m variants using a LD threshold of r2 > 0.1 and a maximal variant distance of 
1Mb (e.g. Fritsche et al. 2019). We then form a set of m* test statistics using the lead variant from 
each locus and apply the B-H or B-Y procedures on these m* test statistics.  
3.2.4 Bayesian approach to multiple testing 
A Bayesian approach to multiple testing involves calculating the posterior probability of the null 
hypotheses of no association given the data. For a single variant j, let the probability of the 
observed data 𝐷 = ^𝑌, 𝑋, 𝐺%_ given the null hypothesis	𝐻&,% be P^𝐷`𝐻&,%_. Then by Bayes’ 
theorem, the probability of the null hypothesis given the data is 
P^	𝐻&,%`	𝐷_ = P^𝐷`𝐻&,%_P^𝐻&,%_P^𝐷`𝐻&,%_P^𝐻&,%_ + P^𝐷`𝐻",%_ a1 − P^𝐻&,%_b = 𝐵𝐹 × 𝑃𝑂𝐵𝐹 × 𝑃𝑂 + 1 
where 𝐵𝐹 = 𝑃^𝐷`𝐻&,%_/𝑃^𝐷`𝐻",%_ is the Bayes factor and 𝑃𝑂 = P^𝐻&,%_/ a1 − P^𝐻&,%_b is the 
prior odds of no association. Here, we make the commonly accepted exchangeability assumption 
that every tested variant has the same prior probability of being associated with the trait, i.e. 1 −P^𝐻&,%_ = 𝜋" and then conservatively estimate 𝜋" as the proportion of tested variants with P < 
5´10-8 in the observed summary statistics. This assumption can be easily relaxed, allowing for 
different priors among tested variants based on their functional annotations (H. Yang & Wang, 
2015). 
For calculating the posterior probability, Wakefield (Wakefield, 2007b) proposed using an 
approximate Bayes Factor (ABF) based on the maximum likelihood estimator (MLE) 𝜃/g  of the 
variant effect 𝜃% as a succinct summary of the observed data 𝐷. Following Wakefield, we 
approximate the BF by 𝑃^𝜃h%`𝐻&,%_/𝑃^𝜃h%`𝐻",%_. Further assuming the sampling distribution of 𝜃/g  is 
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normal with mean 𝜃% and variance 𝑉% and that 𝜃% has a prior normal distribution with mean 0 and 
variance 𝑊%, we calculate the ABF as a ratio of prior predictive densities 𝜃h%|𝐻&,%~𝑁(0, 𝑉%) and 𝜃h%|𝐻",%~𝑁(0, 𝑉% +𝑊%) and use it to approximate the Bayesian false discovery probability (BFDP): 
 𝐴𝐵𝐹% = 1l1 − 𝑟% exp 9−𝑍%#2 𝑟%<		  
 𝐵𝐹𝐷𝑃% = 𝐴𝐵𝐹% × 𝑃𝑂𝐴𝐵𝐹% × 𝑃𝑂 + 1 ( 2 ) 
Here, 𝑟% = 𝑊%/(𝑉% +𝑊%) is the ratio of the prior variance to the total variance and Zj is the test 
statistic for variant j. Calculating the approximate BFDP requires effect size or standard error 
estimates. These may not be included in publicly available GWAS results, which often are limited 
to P-values and/or Z statistics. If necessary, we can reliably estimate the effect size and standard 
error for each variant from its Z statistic and estimated MAF (Zhu et al., 2016b). 
To control the Bayesian FDR (Müller et al., 2004; Wen, 2017) in multiple hypotheses testing at 
level α, we order the BFDPs for m variants from smallest to largest: 𝐵𝐹𝐷𝑃("), … , 𝐵𝐹𝐷𝑃(*) and 
reject all null hypotheses 𝐻&,%, 𝑗	 = 1,… , 𝑘 where k is the largest value for which  ∑ 𝐵𝐹𝐷𝑃,+,	.	"𝑘 ≤ 𝛼 
As with the B-H and B-Y procedures, we use the BFDPs to first cluster the tested variants into loci 
and then apply the BFDP procedure on the lead variant for each locus.  
3.2.5 Joint analysis of multiple traits 
In studies of L correlated traits, there is potentially more power to detect association if the traits 
are analyzed together (Diggle et al., 2002). One approach is to conduct L parallel univariate tests 
and correct for testing multiple traits simultaneously (i.e. divide the P-value thresholds by L); an 
alternative is to jointly analyze the L traits using multivariate test statistics and then apply the usual 
multiple testing procedures to the m resulting tests. 
Consider joint testing of the association between genetic variant j and the L traits under an 
extension of (1): 
40 
 
 𝑌"×1 = 𝑋"×2$ 𝛽2×1 + 𝐺%𝜃%,"×1 + 𝜀%,"×1 ( 3 ) 
where ej is normally distributed with mean 0"×1	and variance  Σ1×1 representing the covariance 
matrix of the trait residuals. In (3), we test the m null hypotheses of no association with any trait: 𝐻&,%: 𝜃",% =	… = 𝜃1,% = 0 for each variant 𝑗 = 1,… ,𝑚.   
For Bonferroni and B-H/B-Y, we jointly analyzed all traits with metaMANOVA (Bolormaa et al., 
2014; Ray & Boehnke, 2018) using the test statistic 𝑡*3456789:7 = 𝑍;𝛺h!"𝑍			 
Here Z is the vector of test statistics for the L traits, 𝛺h is the estimated correlation matrix for the L 
traits, and 𝑡*3456789:7 follows an apoproximate chi-squared distribution with L degrees of 
freedom. We then apply the Bonferroni and B-Y procedures to the multivariate test statistics using 
the same approach as for the univariate study. To control BFDP, we use an extension (Wakefield, 
2007b) of the ABF in (2) to multiple traits (Appendix 3.1). 
3.2.6 Empirical studies 
We evaluated the performance of the multiple testing procedures in the context of common variant 
GWAS by using publicly available meta-analysis results from the GLGC and the GIANT 
consortia. For each procedure, we calculated the empirical false discovery rate (eFDR) as the 
number of false positive loci in the test set (V in Table 3.1) divided by the total number of 
significant loci identified in the test set (R in Table 3.1). Since V is unknown as we do not know 
the truth, we assume that the largest, most recent GWAS represents “truth”. We clustered variants 
declared significant by each procedure into loci using LD clumping. First, we ordered the 
significant variants by P-values and then using the variant with the smallest P-value (i.e. most 
significant) as the lead variant, we grouped all other variants that had LD threshold of r2 > 0.1 with 
the lead variant and within ±1Mb of the lead variant into one locus. Next, we repeated this step on 
the remaining ungrouped variants until all significant variants were clustered into loci. In the test 
set, we labeled loci whose lead variants had r2 > 0.80 with a variant in the truth set with P < 5´10-
8 as true positives; the remaining loci we considered false positives. 
Out of four GWAS meta-analyses (Kathiresan et al., 2009; Teslovich et al., 2010; Willer et al., 
2008, 2013) sequentially carried out for plasma high-density lipoprotein cholesterol (HDL), low-
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density lipoprotein cholesterol (LDL), and triglycerides (TG) levels, we picked the largest meta-
analysis (Willer et al., 2013) with n = 188,577 to serve as the truth set and the second smallest 
meta-analysis (Kathiresan et al., 2009) with n = 19,840 to serve as the test set. We do not present 
results for the other two meta-analyses in the main text because one (Willer et al., 2008) (n = 8,816) 
had limited power and detected few significant variants and the other (Teslovich et al., 2010) (n = 
100,184) had very substantial overlap in samples with the truth set so that there was insufficient 
sample size differences for the truth set to well approximate the truth. Of the 2,373,282 variants 
analyzed in both the truth and test sets, we analyzed the 2,120,069 (89%) with MAF > 5%. 
To evaluate the multiple testing procedures over a wider range of sample sizes and genetic 
architectures, we also applied the procedures to meta-analyses for height and body mass index 
(BMI) from the GIANT consortium (Lango Allen et al., 2010; Speliotes et al., 2010; Yengo et al., 
2018). We present results for these meta-analyses from a larger set of sequential meta-analyses 
(Lango Allen et al., 2010; Locke et al., 2015; Speliotes et al., 2010; Wood et al., 2014; Yengo et 
al., 2018) using the same rationale as described above for GLGC: the largest, most recent meta-
analyses (Yengo et al., 2018) for height and BMI (n = 694,529 and n = 681,275, respectively) 
served as the truth sets and the smallest meta-analyses (Lango Allen et al., 2010; Speliotes et al., 
2010) for each trait (n = 133,653 and n = 123,865) served as the test sets. Of the 2,282,242 variants 
analyzed in both meta-analyses for height, we analyzed the 2,036,404 (89%) with MAF > 5%. Of 
the 2,282,195 variants in both meta-analyses for BMI, we analyzed the 2,035,656 (89%) with MAF 
> 5%. 
For univariate analysis of each lipid and anthropometric trait, we used published meta-analyses 
results. Detailed descriptions of the statistical analyses for each of the results can be found in their 
respective papers (Kathiresan et al., 2009; Lango Allen et al., 2010; Speliotes et al., 2010; Willer 
et al., 2013; Yengo et al., 2018). For multivariate analysis of the three lipid traits together, we 
combined the univariate results using the appropriate multivariate extension for each of the 






3.2.7 Simulation studies 
To evaluate the multiple testing procedures when truth is known, we generated 1,000 replicate 
datasets based on the empirical association structures observed in the latest GWAS for each of the 
five traits.  
To mimic the GLGC test set which consisted of European cohorts, we randomly sampled 19,840 
individuals from 276,791 unrelated individuals of white British ancestry in the UK BioBank 
dataset. For each replicate, we used the genotypes of these individuals to generate outcomes on n 
= 19,840 individuals for each lipid trait following model (1). We assumed the trait value Y is 
inverse normalized to maintain consistency with the empirical studies, we estimated the causal 
variant effect sizes q from the latest GLGC GWAS (the truth set), and the error term is normally 
distributed with mean 0 and variance equal to 1 minus the proportion of trait variance explained 
by the simulated causal variants. We ran association analysis with each replicate dataset using a 
linear regression model with no additional covariates. We took a similar approach for simulating 
height and BMI based on the GIANT dataset using separate generation models for the two traits.    
3.3 Results  
We applied the multiple testing procedures to HDL, LDL, TG, height, and BMI to assess their 
performances for different sample sizes and genetic structures. 
3.3.1 P-value threshold 
Applying various fixed P-value thresholds to the empirical GLGC and GIANT test sets, we 
observed as expected that the empirical false discovery rate (eFDR) generally increased as the P-
value threshold increased (Table 3.2). The lone exception (for HDL) likely reflected statistical 




Table 3.2: Empirical and simulation results for P-value thresholds 
Trait Threshold (P-value) 
Empirical  Simulation 
Positives eFDRb Δ in #of sig. loci (% true) 
 Positives eFDR Δ in #of sig. loci (% true) False Truea  False True 
HDL 
 (ntest = 19,840 
ntruth = 188,577) 
5´10-8 1 16 5.9% -  0.28 9.5 2.9% - 
5´10-7 1 18 5.3% +2 (100%)  0.89 12 6.7% +3.6 (83%) 
5´10-6 8 21 28% +10 (30%)  4.2 17 20% +8.2 (60%) 
LDL 
(ntest = 19,840 
ntruth = 188,577) 
5´10-8 0 14 0% -  0.19 13 1.5% - 
5´10-7 3 16 16% +5 (40%)  0.71 16 4.2% +3.9 (87%) 
5´10-6 10 19 34% +10 (30%)  4.6 22 17% +9.1 (58%) 
TG 
(ntest = 19,840 
ntruth = 188,577) 
5´10-8 1 8 11% -  0.11 9.0 1.2% - 
5´10-7 2 10 17% +3 (67%)  0.54 10 4.9% +1.9 (77%) 
5´10-6 6 15 29% +9 (56%)  3.8 13 22% +6.1 (47%) 
Height 
(ntest = 133,653 
ntruth= 693,529) 
5´10-8 0 157 0% -  1.6 181 0.89% - 
5´10-7 1 217 0.46% +61 (98%)  4.9 223 2.2% +46 (93%) 
5´10-6 2 312 0.64% +96 (99%)  16 283 5.4% +72 (84%) 
BMI 
 (ntest = 123,865 
ntruth = 681,275) 
5´10-8 0 22 0% -  0.62 39 1.6% - 
5´10-7 0 37 0% +15 (100%)  2.7 58 4.4% +22 (90%) 
5´10-6 1 55 1.8% +19 (95%)  11 90 11% +41 (79%) 
Note: a Number of loci in truth set for HDL: 89, LDL: 72, TG: 60, height: 1100, BMI: 724. 
b eFDR is calculated as number of false positives divided by sum of true and false positives. 
For height and BMI, we identified substantially more loci by relaxing the threshold from P = 5´10-
8 to P = 5´10-7 with nearly all these new loci being true positives (Table 3.2 and Figure 3.1): 60 of 
61 (98%) for height; 15 of 15 (100%) for BMI. Further relaxing the threshold from P = 5´10-7 to 
P = 5´10-6 maintained high proportions of true positives among the additional loci: 95 of 96 (99%) 
for height, 18 of 19 (95%) for BMI. For the lipid traits in the GLGC test set, relaxing the threshold 
from P = 5´10-8 to P = 5´10-7 resulted in HDL, LDL, and TG gaining 2, 5, and 3 loci with 2, 2, 
and 2 (100%, 40%, and 67%) being true positives. Further relaxing the threshold from P = 5´10-7 
to P = 5´10-6 resulted in ≤ 56% of the additional loci being true positives for the lipid traits. 
We observed in the GLGC- and GIANT-based simulated datasets that the average eFDR increased 
as the P-value threshold increased for all traits (Table 3.2); the inconsistency described before for 
the empirical HDL test set disappeared when we averaged over 1,000 simulation replicates. 
Consistent with the empirical results, there was a clear difference in the proportion of true positives 
between the lipid and anthropometric traits in the simulated results (Table 3.2). Relaxing the 
threshold from P = 5´10-8 to P = 5´10-7 in the simulated datasets resulted in an average of 77% to 
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87% of the additional loci being true positives for the lipid traits and 93% and 90% for height and 
BMI. Further relaxing the threshold from P = 5´10-7 to P = 5´10-6 resulted in 47% to 60% of the 
additional loci being true positives for lipids, and 84% and 79% for height and BMI. 
Figure 3.1: Manhattan plot of empirical P-value thresholds 
 
Plots of different P-value thresholds applied to empirical test sets for HDL, BMI, and height. Colored 
variants depict true positive loci (blue) and false positive loci (red) for variants with P-value ≥ 5x10-8. 





To address whether the higher rates of true positives we observed when relaxing the P-value 
threshold for height and BMI compared to those for lipids were the result of differences in sample 
sizes, we simulated test sets for height and BMI at the same sample sizes (n=8,816 and n = 19,840) 
as the GLGC meta-analyses. For both traits, an increase in sample size generally led to higher 
proportion of true positives gained from relaxing the P-value threshold (Table 3.3), suggesting a 
better yield of true positives by using relaxed thresholds in larger samples than in smaller ones. 
Table 3.3: Effect of sample size on simulation results for P-value thresholds 
Trait Threshold (P-value) 
n = 8,816  n = 19,840 
Positives eFDRb 
Δ sig. loci 
(% True 
positive) 
 Positives eFDR 
Δ sig. loci 
(% True 
positive) False Truea  False True 
Height 
5´10-8 0.04 0.90 4.3% -  0.03 11 0.27% - 
5´10-7 0.40 2.2 15% +1.7 (78%)  0.32 18 1.7% +7.4 (96%) 
5´10-6 3.0 5.9 34% +6.3 (58%)  3.6 30 11% +15 (79%) 
BMI 
5´10-8 0.04 0.20 17% -  0.09 1.5 5.7% - 
5´10-7 0.34 0.41 45% +0.51 (41%)  0.46 2.4 16% +1.3 (72%) 
5´10-6 3.1 1.2 73% +3.5 (21%)  3.2 4.6 41% +5.0 (44%) 
Note: a Number of loci in truth set for HDL: 89, LDL: 72, TG: 60, height: 1100, BMI: 724. 
b eFDR is calculated as number of false positives divided by sum of true and false positives. 
 
3.3.2 Benjamini-Hochberg and Benjamini-Yekutieli procedures 
As expected, empirical results for the two FDR controlling procedures showed B-Y was 
conservative, resulting in eFDR far below the target FDR threshold for all traits at commonly used 
(5-15%; Table 3.4) and more extreme (1-25%; Supplementary Table 3.1) thresholds. B-H 
controlled the eFDR at the target thresholds (Table 3.5 and Supplementary Table 3.2) for height 
and BMI but not lipid traits, likely because the number of lipid trait discoveries was modest (≤ 26 
loci for B-H) so that even a small change in numbers of true and false positives substantially 
influenced estimated eFDR. 
Simulation results for B-Y were consistent with empirical results in showing that B-Y is overly 
conservative for all five traits and all target FDR thresholds (Table 3.4 and Supplementary Table 
3.1). For example, the observed eFDR for target threshold of 15% is < 3.4% for all traits. Compared 
to the empirical results, B-H did a better job of controlling eFDR at the commonly used thresholds 
(Table 3.5) for all traits; only for height at 5% and BMI at 5% did B-H show noticeable inflation 
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in eFDR (6.8% for height, 7.9% for BMI). When we relaxed our criterion for defining a true 
positive (see below), inflations for height and BMI decreased (eFDR = 5.5% and 5.2%). eFDR 
was well-controlled at high thresholds 20% and 25% for all five traits but poorly-controlled at low 
thresholds 1% and 3% (Supplementary Table 3.2). 
Table 3.4: Empirical and simulation results for Benjamini-Yekutieli procedure 
Trait Threshold (FDR) 
Empirical  Simulation 
Positives eFDRb  Positives eFDR False Truea  False True 
HDL 
 (ntest = 19,840  
ntruth = 188,577) 
5% 0 14 0%  0.17 8.2 2.0% 
10% 1 16 5.9%  0.25 9.1 2.7% 
15% 1 16 5.9%  0.31 9.6 3.1% 
LDL 
(ntest = 19,840  
ntruth = 188,577) 
5% 0 14 0%  0.13 12 1.1% 
10% 0 14 0%  0.19 13 1.5% 
15% 0 15 0%  0.26 13 1.9% 
TG 
(ntest = 19,840  
ntruth = 188,577) 
5% 0 8 0%  0.05 8.5 0.58% 
10% 0 8 0%  0.06 8.7 0.68% 
15% 1 8 11%  0.11 9.0 1.2% 
Height 
(ntest = 133,653 
ntruth = 693,529) 
5% 0 197 0%  4.3 217 2.0% 
10% 1 234 0.43%  6.3 235 2.6% 
15% 1 249 0.40%  7.9 246 3.1% 
BMI 
(ntest = 123,865 
ntruth = 681,275) 
5% 0 20 0%  0.83 41 2.0% 
10% 0 22 0%  1.4 47 2.9% 
15% 0 26 0%  1.8 52 3.4% 
Note: a Number of loci in truth set for HDL: 89, LDL: 72, TG: 60, height: 1100, BMI: 724. 
b eFDR is calculated as number of false positives divided by sum of true and false positives. 
Table 3.5: Empirical and simulation results for Benjamini-Hochberg procedure 
Trait Threshold (FDR) 
Empirical  Simulation 
Positives eFDRb  Positives eFDR False Truea  False True 
HDL 
 (ntest = 19,840 
ntruth = 188,577) 
5% 1 18 5.3%  0.70 12 5.6% 
10% 5 18 22%  1.3 13 8.5% 
15% 6 20 23%  1.7 14 11% 
LDL 
(ntest = 19,840 
ntruth = 188,577) 
5% 3 16 16%  0.67 16 4.0% 
10% 4 16 20%  1.1 18 6.0% 
15% 7 17 29%  1.7 18 8.6% 
TG 
(ntest = 19,840 
ntruth = 188,577) 
5% 2 9 18%  0.32 10 3.1% 
10% 5 10 33%  0.63 11 5.6% 
15% 5 10 33%  0.96 11 8.0% 
Height 
(ntest = 133,653 
ntruth = 693,529) 
5% 2 351 0.57%  22 301 6.8% 
10% 4 421 0.94%  37 331 10% 
15% 8 468 1.7%  50 351 13% 
BMI 
(ntest = 123,865 
ntruth = 681,275) 
5% 1 41 2.4%  6.6 77 7.9% 
10% 1 47 2.1%  11 91 11% 
15% 1 55 1.8%  16 102 14% 
Note: a Number of loci in truth set for HDL: 89, LDL: 72, TG: 60, height: 1100, BMI: 724. 
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b eFDR is calculated as number of false positives divided by sum of true and false positives. 
We investigated whether FDR control for B-H and B-Y extended across sample sizes by using 
simulated datasets for height and BMI at n = 8,816, n = 19,840 and n = 133,653 (height) or 123,865 
(BMI). Both procedures controlled eFDR at the target FDR thresholds 5-15% for height 
(Supplementary Table 3.4 and 3.5); BMI showed inflation under B-H for all test sets which 
disappeared under the relaxed definition of true positives. 
3.3.3 BFDP 
For the BFDP procedure, we estimated the prior probability of association at a variant site (𝜋") 
separately for each test set using the proportion of tested variants with P < 5´10-8. Empirical results 
showed that eFDR was well controlled for height and BMI at target Bayesian FDR thresholds 1-
25% but poorly controlled for lipid traits (Table 3.6 and Supplementary Table 3.3), again likely 
due to the smaller number of discoveries for lipid traits (≤ 24 loci for BFDP).     
Simulation results for BFDP showed that eFDR was generally well controlled at target Bayesian 
FDR thresholds 5-15% (Table 3.6) for all traits except height (eFDR = 8.1%, 13%, and 17%). For 
more extreme thresholds (Supplementary Table 3.3), eFDR was controlled at 1 and 3% for lipid 
traits, albeit with inflation for HDL at 1%; eFDR was controlled at 20% and 25% for all traits. 





Empirical   Simulation 𝜋!"a Positives eFDRc  𝜋!"d Positives eFDR False Trueb  False True 
HDL               
(ntest = 19,840  
ntruth = 188,577) 
5% 
1.3´10-4 
1 17 5.6%  
8.7´10-5 
0.41 10 4.0% 
10% 4 17 19%  0.76 12 6.1% 
15% 6 18 25%  1.2 13 8.4% 
LDL                
(ntest = 19,840  
ntruth = 188,577) 
5% 
1.3´10-4 
2 17 11%  
9.6´10-5 
0.37 14 2.5% 
10% 5 17 23%  0.83 16 4.9% 
15% 6 18 25%  1.3 18 7.0% 
TG                  
(ntest = 19,840  
ntruth = 188,577) 
5% 
2.1´10-4 
1 10 9.1%  
1.6´10-4 
0.36 9.8 3.6% 
10% 4 10 29%  1.0 11 8.4% 
15% 4 12 25%  1.6 12 12% 
Height             
(ntest = 133,653 
ntruth = 693,529) 
5% 
2.0´10-3 
2 338 0.59%  
2.9´10-3 
28 317 8.1% 
10% 7 406 1.7%  51 356 13% 
15% 9 468 1.9%  76 385 17% 
BMI                
(ntest = 123,865 
ntruth = 681,275) 
5% 
3.6 ´10-4 
0 35 0%  
5.2´10-4 
3.9 67 5.4% 
10% 0 43 0%  7.2 82 8.0% 
15% 0 50 0%  11 93 10% 
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Note: a 𝜋!" is the estimated prior probability of association at a variant site equal to the proportion of tested 
variants with P-value  <  5´10-8. 
b Number of loci in truth set for HDL: 89, LDL: 72, TG: 60, height: 1100, BMI: 724. 
c eFDR is calculated as number of false positives divided by sum of true and false positives. 
d Average 𝜋!" in 1,000 replicate datasets. 
   
3.3.4 Multi-trait analysis results for lipids 
In empirical results (Supplementary Table 3.6), the P = 5´10-8 threshold had the lowest eFDR for 
the parallel univariate tests both adjusted (Bonferroni corrected threshold of 1.67´10-8) and 
unadjusted (5´10-8) for testing three traits. For the multivariate tests, the P = 5´10-8 and P = 5´10-
7 thresholds had identical eFDR of 0%. Between the three sets of thresholds, the multivariate 
analysis had the lowest eFDR as well as the highest proportion of true positive discoveries when 
relaxing the P-value thresholds. For both the B-H and BFDP procedures, multivariate tests had 
lower eFDR than the univariate tests but only the multivariate B-H procedure controlled the eFDR 
at target thresholds 5-15%.  
In simulation results (Supplementary Table 3.7), the P = 5´10-8 threshold had the lowest eFDR for 
all three sets of tests. Consistent with empirical results, multivariate tests had the lowest eFDR at 
all three P-value thresholds and better true positive rate for relaxing thresholds compared with the 
univariate tests. For the B-H and BFDP procedure, both univariate and multivariate tests controlled 
the eFDR at target thresholds 5-15%. 
3.3.5 Sensitivity analyses 
We defined true positives in the test set strictly as loci whose lead variants had LD threshold of r2 
> 0.80 with a genome-wide significant (P-value < 5´10-8) variant in the truth set. We chose this 
strict criterion to avoid underestimating the number of false positives in our analysis but it likely 
led to overestimation of eFDR. To assess the impact of this, we repeated our simulation analyses 
using a relaxed definition of true positives by lowering the LD threshold requirement to 0.60 and 
the P-value requirement to 5´10-7 (Supplementary Table 3.8). As expected, under this relaxed 
definition we observed fewer false positives and occurrences of inflated eFDR largely disappeared 
as well. For example, simulation results for height using the BFDP procedure at FDR thresholds 
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of 10% and 15% showed eFDR of 13% and 17% under the strict definition and 10% and 14% 
under the relaxed definition. 
In addition to our LD-based definitions, we used physical distance to define loci and true positives. 
We grouped variants within ±1Mb of the lead variants into loci and defined true positives as loci 
whose lead variants were within ±50kb of a genome-wide significant variant in the truth set. The 
analyses results (Supplementary Table 3.9) showed that the distance-based definitions led to 
smaller numbers of true and false positives for all traits and multiple testing procedures. 
3.4 Discussion 
In this paper, we leverage the sequentially growing nature of GWAS meta-analyses to evaluate 
true and false positive rate of P-value thresholds and other multiple testing procedures. Although 
the standard procedure for identifying significant associations in common variant GWAS is to use 
a P-value threshold of 5´10-8, relaxing the significance criteria, whether through use of less 
stringent P-value thresholds or controlling for alternative error rate measures such as FDR 
(depending on the target threshold) increases the number of identified loci. We demonstrated that 
a substantial proportion of the additional loci identified are true positives, with larger proportions 
of true positives in analysis of larger samples. 
3.4.1 Application to downstream analyses 
GWAS identify trait-associated variants and loci based on association analysis of millions of 
variants. The identified loci are often further validated in replication studies before being used for 
statistical and functional analyses to identify causal genes, variants, and mechanisms. Although 
relaxed P-value thresholds are often used to generate the list of loci for replication, the expected 
true and false discovery rates under different thresholds have not been quantified. We showed by 
simulation for common variant GWAS with sample size > 100,000 that 90-93% of additional 
discoveries with P-values between 5´10-8 and 5´10-7 were true positives, representing true 
associations that would be lost under a more stringent threshold. However, for more modest sample 
sizes (~20,000), our simulation showed that only 77-87% of additionally discovered loci with P-
values between 5´10-8 and 5´10-7 were true positives. Here, investigators should exercise caution 
when relaxing the significance threshold for replication studies as the increase to replicated 
associations may not outweigh the inflated false discovery rate. 
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For follow-up studies such as constructing animal models where the per-locus cost of follow-up is 
high, a stringent P-value threshold of 5´10-8 is ideal in both large and modest-sized studies to 
generate a highly accurate list of associated loci. However, such threshold may be unhelpfully 
conservative for analyses where including (many) more true loci at the cost of (a few) more false 
positives is acceptable such as gene-set enrichment or pathway analysis. In these situations, a 
relaxed threshold of 5´10-7 or even 5´10-6 may be better served to prioritize GWAS results for 
downstream analyses. The utility of these relaxed thresholds can be seen in the DEPICT (Pers et 
al., 2015) software designed for gene prioritization, gene set enrichment analysis, and identifying 
enriched tissue or cell types at significant loci discovered by GWAS. Here, the authors recommend 
using DEPICT on all GWAS loci with P-value < 1×10-5 to improve discovery of causal gene sets 
for direct functional follow-ups.    
3.4.2 FDR- and Bayesian FDR-control 
FDR-control is an appropriate choice for practitioners who are willing to tolerate some proportion 
of false positive discoveries as long as it can be controlled below a target threshold. At equivalent 
thresholds, controlling the FDR is less conservative than controlling the FWER and thus expands 
the GWAS-identified set of associated loci for downstream analysis, especially for highly 
polygenic traits. We showed that the B-H procedure adapted for GWAS (see Methods) provided 
approximate control of the empirical estimate of FDR (eFDR) for the tested traits and samples at 
target thresholds 5-25%. The B-Y procedure is far too conservative in GWAS as the correction 
factor which removes assumptions on the dependency structure of test statistics is unnecessary 
under the adapted B-H procedure which forms independent test statistics using the lead variants 
from each locus. 
For BFDP, a Bayesian alternative to B-H, we estimated the proportion of trait-associated variants 𝜋" using the proportion of tested variants with P-values less than 5´10-8 and found the Bayesian 
FDR to be reasonably well controlled at thresholds of 5-25%. For comparison, when we estimated 𝜋" as the number of loci with lead variant P < 5´10-8 divided by 1 million (an estimate for the total 
number of independent common variants in the genome (Altshuler et al., 2005; Pe’er et al., 
2008b)), the resulting lower 𝜋" estimates led to conservative results (Supplementary Table 3.10). 
3.4.3 Comparison between procedures 
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A P-value threshold has the advantages of familiarity, simplicity, and ease of implementation while 
B-H and BFDP control the eFDR across a range of sample sizes. In simulations, both B-H and 
BFDP controlled the eFDR for height and HDL, two traits with different genetic architectures and 
for which we analyzed very different sample sizes (n = 133,653 and n = 19,840). In contrast, 95% 
of discoveries at a P-value threshold of 5´10-6 were true positives for height while only 80% were 
true positives for HDL. A stringent P-value threshold is needed if our primary goal is to limit the 
number of false positives as both B-H and BFDP struggled to control the eFDR at low target 
thresholds 1% and 3%. 
3.4.4 Summary 
In this study, we evaluated the performance of four procedures for multiple testing corrections in 
the context of common variant GWAS: P-value thresholds, B-H and B-Y for FDR control, and 
BFDP for Bayesian FDR control. We have shown that for studies based on large samples, using a 
less stringent P-value threshold of 5´10-7 or use of FDR-controlling procedure (B-H) at target 
threshold of 5% substantially increases the number of true positive discoveries that can be used in 
downstream analyses while only modestly increasing false positives compared with the commonly 
used 5´10-8 P-value threshold. The latter threshold remains the preferred choice for modest-sized 
studies or when a stringently curated list of loci is desired. Finally, we show that FDR-control 





3.5 Supplementary materials 
Appendix 3.1: Multivariate BFDP 
Consider joint testing of the association between a genetic variant and L traits under model (3). 
To match our analysis, we set L = 3 for the rest of this section but this multivariate extension can 
be applied to any number of traits. 
As in the univariate case described in Methods and in Wakefield (2007),23 we approximate the 
multivariate Bayes’ factor by 𝑃^𝜽g`𝐻&_/𝑃^𝜽g`𝐻"_ where 𝜽g = (𝜃h", 𝜃h#, 𝜃h<) is the estimated vector 
of variant effect sizes for the three traits. We assume the sampling distribution of 𝜽g is 
multivariate normal with mean 𝜽 and variance 𝑽 and that 𝜽 has a prior multivariate normal 
distribution with mean 𝟎 and variance 𝑾. If 𝝆 is the 3´3 matrix of correlation between the traits 
and 𝜌,% is the correlation between traits i and j, then 
𝑽 = x 𝑉" 𝜌"#l𝑉"𝑉# 𝜌"<l𝑉"𝑉<𝜌#"l𝑉#𝑉" 𝑉# 𝜌#<l𝑉#𝑉<𝜌<"l𝑉<𝑉" 𝜌<#l𝑉<𝑉# 𝑉< y 
𝑾 = x 𝑊" 𝜌"#l𝑊"𝑊# 𝜌"<l𝑊"𝑊<𝜌#"l𝑊#𝑊" 𝑊# 𝜌#<l𝑊#𝑊<𝜌<"l𝑊<𝑊" 𝜌<#l𝑊<𝑊< 𝑊< y 
where 𝑉+ is the sample variance and 𝑊+ is the prior variance for trait k. Finally, the multivariate 
approximate Bayes’ factor (ABF) can be calculated as a ratio of prior predictive densities 𝜽g|𝐻&~𝑀𝑉𝑁(𝟎, 𝑽) and 𝜽g|𝐻"~𝑀𝑉𝑁(𝟎, 𝑽 +𝑾) and used to approximate the BFDP: 
𝐴𝐵𝐹*=>4, = |𝑽|!"#|𝑽 +𝑾|"# exp 9𝜽g$(−𝑽!" + (𝑽 +𝑾)!")𝜽g2 < 
𝐵𝐹𝐷𝑃*=>4, = 𝐴𝐵𝐹*=>4, × 𝑃𝑂𝐴𝐵𝐹*=>4, × 𝑃𝑂 + 1 
For the prior odds of no association, we estimate the prior probability of being associated with 
the three traits (𝜋"{*=>4,) as the average of the 𝜋"{’s from each trait which is calculated as 
described in Methods.  
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3.6 Supplementary Tables 
 
Supplementary Table 3.1: Benjamini-Yekutieli results for extreme thresholds 
Trait Threshold (FDR) 
Empirical  Simulation 




1% 0 14 0%  0.08 7.0 1.1% 
3% 0 14 0%  0.13 7.9 1.6% 
20% 1 16 5.9%  0.34 10 3.3% 




1% 0 14 0%  0.06 10 0.59% 
3% 0 14 0%  0.08 11 0.72% 
20% 0 15 0%  0.27 14 1.9% 




1% 0 8 0%  0.02 7.8 0.26% 
3% 0 8 0%  0.03 8.3 0.36% 
20% 1 8 11%  0.13 9.1 1.4% 




1% 0 157 0%  1.8 185 0.95% 
3% 0 180 0%  3.3 206 1.6% 
20% 1 272 0.37%  9.3 254 3.5% 




1% 0 19 0%  0.22 31 0.71% 
3% 0 20 0%  0.51 37 1.4% 
20% 0 29 0%  2.2 55 3.9% 
25% 0 32 0%  2.7 58 4.4% 
Note: a Number of loci in truth set for HDL: 89, LDL: 72, TG: 60, height: 1100, BMI: 724. 
b eFDR is calculated as number of false positives divided by sum of true and false positives.  
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Supplementary Table 3.2: Benjamini-Hochberg results for extreme thresholds 
Trait Threshold (FDR) 
Empirical  Simulation 




1% 1 16 5.9%  0.31 9.6 3.1% 
3% 1 17 5.6%  0.50 11 4.3% 
20% 7 20 26%  2.2 15 13% 




1% 0 15 0%  0.26 13 1.9% 
3% 0 15 0%  0.45 15 2.9% 
20% 7 18 28%  2.2 19 10% 




1% 1 8 11%  0.11 9.0 1.2% 
3% 2 8 20%  0.24 9.6 2.5% 
20% 5 10 33%  1.3 12 10% 




1% 1 249 0.40%  7.90 246 3.1% 
3% 2 309 0.64%  15 281 5.2% 
20% 10 496 2.0%  63 368 15% 




1% 0 26 0%  1.8 52 3.4% 
3% 0 37 0%  4.3 68 6.0% 
20% 3 61 4.7%  22 111 16% 
25% 3 66 4.3%  27 118 19% 
Note: a Number of loci in truth set for HDL: 89, LDL: 72, TG: 60, height: 1100, BMI: 724. 
b eFDR is calculated as number of false positives divided by sum of true and false positives.  
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0 14 0%  
8.7´10-5 
0.18 7.5 2.3% 
3% 1 16 5.9%  0.30 9.0 3.2% 
20% 8 18 31%  1.8 14 11% 






0 15 0%  
9.6´10-5 
0.12 11 1.1% 
3% 1 16 5.9%  0.26 13 1.9% 
20% 7 19 27%  2.2 19 10% 






0 8 0%  
1.6´10-4 
0.07 8.1 0.85% 
3% 1 9 10%  0.20 9.2 2.1% 
20% 4 14 22%  2.6 12 17% 






1 234 0.43%  
2.9´10-3 
8.7 254 3.3% 
3% 2 299 0.66%  18 294 5.9% 
20% 16 523 3.0%  106 410 21% 






0 25 0%  
5.2´10-4 
1.1 46 2.2% 
3% 0 31 0%  2.6 59 4.1% 
20% 1 57 1.7%  15 103 13% 
25% 1 65 1.5%  21 112 16% 
Note: a 𝜋!" is the estimated prior probability of association at a variant site equal to the proportion of tested 
variants with P-value less than 5´10-8. 
b Number of loci in truth set for HDL: 89, LDL: 72, TG: 60, height: 1100, BMI: 724. 
c eFDR is calculated as number of false positives divided by sum of true and false positives. 
d Average 𝜋!" in 1,000 replicate datasets.  
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Supplementary Table 3.4: Effect of sample size on simulation results for Benjamini-Yekutieli 
Trait Threshold (FDR) 
n=8,816  n=19,840  n=133,653 or 123,865 
Positives eFDRb  Positives eFDR  Positives eFDR 
False Truea  False True  False True 
Height 
5% 0 0.22 0%  0.01 9.0 0.11%  4.3 217 2.0% 
10% 0 0.30 0%  0.01 11 0.10%  6.3 235 2.6% 
15% 0 0.35 0%  0.06 12 0.51%  7.9 246 3.1% 
BMI 
5% 0.01 0.05 17%  0.01 0.99 1.0%  0.83 41 2.0% 
10% 0.01 0.07 13%  0.01 1.1 0.88%  1.4 47 2.9% 
15% 0.01 0.08 11%  0.01 1.2 0.81%  1.8 52 3.4% 
Note: a Number of loci in truth set for HDL: 89, LDL: 72, TG: 60, height: 1100, BMI: 724. 




Supplementary Table 3.5: Effect of sample size on simulation results for Benjamini-Hochberg 
Trait Threshold (FDR) 
n=8,816  n=19,840  n=133,653 or 123,865 
Positives eFDRb  Positives eFDR  Positives eFDR 
False Truea  False True  False True 
Height 
5% 0.05 0.87 5.4%  0.27 18 1.5%  22 301 6.8% 
10% 0.12 1.2 9.0%  0.85 22 3.7%  37 331 10% 
15% 0.18 1.5 11%  1.5 25 5.6%  50 351 13% 
BMI 
5% 0.01 0.17 5.6%  0.11 1.5 6.7%  6.6 77 7.9% 
10% 0.05 0.22 19%  0.23 1.8 11%  11 91 11% 
15% 0.08 0.25 24%  0.33 2.1 14%  16 102 14% 
Note: a Number of loci in truth set for HDL: 89, LDL: 72, TG: 60, height: 1100, BMI: 724. 




Supplementary Table 3.6. Combined univariate and multivariate empirical results for lipids 
 
Metric Threshold 
Combined univariate  Multivariate 







5´10-8 2 38 5.0%  0 41 0% 
5´10-7 6 47 11%  0 45 0% 
5´10-6 24 58 29%  2 52 3.7% 
Adjusted 
1.67´10-8 0 35 0%  
Not applicable 1.67´10-7 2 40 4.8%  
1.67´10-6 13 53 20%  
B-H 
5% 6 53 10%  2 52 3.7% 
10% 14 60 19%  5 52 8.8% 
15% 18 60 23%  8 53 13% 
BFDPc  
5% 7 57 11%  5 58 7.9% 
10% 15 61 20%  10 61 14% 
15% 19 66 22%  14 65 18% 
Note: a Number of loci in truth set for all three lipids: 139 (non-overlapping), height: 1100, BMI: 724. 
b eFDR is calculated as number of false positives divided by sum of true and false positives. 
c 𝜋!"’s for univariate analyses is 1.3´10-4 for HDL, 1.3´10-4 for LDL, and 2.1´10-4 for TG. 𝜋!""#$%& is 
1.7´10-4, the average of the 𝜋!"’s for the three lipid traits. 
 
 
Supplementary Table 3.7. Combined univariate and multivariate simulation results for lipids 
 
Metric Threshold 
Combined univariate  Multivariate 







5´10-8 0.43 22 1.9%  0.57 30 1.9% 
5´10-7 1.7 28 5.7%  1.6 37 4.1% 
5´10-6 10 36 22%  6.4 47 12% 
Adjusted 
1.67´10-8 0.26 20 1.3%  
Not applicable 1.67´10-7 0.78 25 3.0%  
1.67´10-6 4.4 32 12%  
B-H 
5% 1.1 32 3.3%  2.4 40 5.7% 
10% 2.2 35 5.9%  3.9 43 8.3% 
15% 3.2 37 8.0%  5.2 46 10% 
BFDPc 
5% 1.2 31 3.7%  1.6 34 4.5% 
10% 2.6 35 6.9%  3.1 38 7.5% 
15% 4.1 38 9.7%  4.8 40 11% 
Note: a Number of loci in truth set for all three lipids: 139 (non-overlapping), height: 1100, BMI: 724. 
b eFDR is calculated as number of false positives divided by sum of true and false positives. 
c Average 𝜋!"’s for univariate analyses is 7.7´10-5 for HDL, 8.7´10-5 for LDL, and 1.4´10-4 for TG. 𝜋!""#$%& is 9.9´10-5, the average of the 𝜋!"’s for the three lipid traits.  
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P-value | FDR 
P-value threshold  B-H  BFDP 
 Positives eFDR 
 Positives eFDR 
 Positives eFDR 
False Truea  False True  False True 
HDL               
(ntest = 19,840           
ntruth = 188,577) 
5´10-8 | 5% 0.13 9.6 1.3%  0.42 12 3.3%  0.16 10 1.5% 
5´10-7 | 10% 0.58 13 4.4%  0.92 14 6.3%  0.44 12 3.6% 
5´10-6 | 15% 3.6 18 17%  1.3 15 8.0%  0.80 13 5.7% 
LDL               
(ntest = 19,840           
ntruth = 188,577) 
5´10-8 | 5% 0.11 13 0.84%  0.51 16 3.1%  0.27 14 1.8% 
5´10-7 | 10% 0.55 16 3.2%  0.93 18 5.0%  0.67 16 3.9% 
5´10-6 | 15% 4.0 22 15%  1.5 19 7.2%  1.1 18 5.9% 
TG                  
(ntest = 19,840           
ntruth = 188,577) 
5´10-8 | 5% 0.06 9.2 0.66%  0.23 10 2.2%  0.25 9.9 2.5% 
5´10-7 | 10% 0.43 11 3.9%  0.50 11 4.5%  0.79 11 6.6% 
5´10-6 | 15% 3.4 14 20%  0.80 11 6.7%  1.4 12 10% 
Height            
(ntest = 133,653 
ntruth = 693,529) 
5´10-8 | 5% 1.1 181 0.62%  18 306 5.5%  23 322 6.6% 
5´10-7 | 10% 3.7 225 1.6%  30 337 8.3%  43 364 10% 
5´10-6 | 15% 13 289 4.3%  42 360 11%  65 396 14% 
BMI                
(ntest = 123,865 
ntruth = 681,275) 
5´10-8 | 5% 0.37 39 0.94%  4.3 79 5.2%  2.4 69 3.4% 
5´10-7 | 10% 1.5 59 2.5%  8.2 94 8.0%  4.7 84 5.3% 
5´10-6 | 15% 8.0 93 7.9%  12 106 10%  7.6 96 7.3% 
Note: a True positive defined as a locus whose lead variant had r2 > 0.60 with a variant in the truth set with 








P-value | FDR 
P-value threshold  B-H  BFDP 
 Positives eFDR 
 Positives eFDR 
 Positives eFDR 
False Truea  False True  False True 
HDL 
(ntest = 19,840 
ntruth = 188,577) 
5´10-8 | 5% 0.07 7.8 0.89%  0.20 9.4 2.1%  0.06 8.0 0.75% 
5´10-7 | 10% 0.35 10 3.4%  0.41 10 3.8%  0.19 9.3 2.0% 
5´10-6 | 15% 2.9 14 17%  0.69 11 5.9%  0.46 10 4.2% 
LDL 
(ntest = 19,840 
ntruth = 188,577) 
5´10-8 | 5% 0.02 12 0.17%  0.24 13 1.8%  0.12 12 0.96% 
5´10-7 | 10% 0.33 14 2.3%  0.53 14 3.5%  0.43 14 3.0% 
5´10-6 | 15% 3.2 17 16%  0.85 15 5.4%  0.90 15 5.6% 
TG 
(ntest = 19,840 
ntruth = 188,577) 
5´10-8 | 5% 0.05 8.7 0.57%  0.18 9.5 1.9%  0.17 9.2 1.8% 
5´10-7 | 10% 0.32 9.8 3.2%  0.35 9.9 3.4%  0.58 10 5.4% 
5´10-6 | 15% 3.0 12 20%  0.58 10 5.4%  1.3 11 10% 
Height 
(ntest = 133,653 
ntruth = 693,529) 
5´10-8 | 5% 0.08 172 0.05%  3.7 263 1.4%  8.7 291 2.9% 
5´10-7 | 10% 0.49 207 0.24%  7.3 284 2.5%  20 324 5.8% 
5´10-6 | 15% 2.8 255 1.1%  11 297 3.6%  34 348 9.0% 
BMI 
(ntest = 123,865 
ntruth = 681,275) 
5´10-8 | 5% 0.14 38 0.37%  2.5 75 3.2%  1.3 67 1.9% 
5´10-7 | 10% 0.81 57 1.4%  4.7 90 5.0%  2.9 82 3.4% 
5´10-6 | 15% 4.9 90 5.1%  6.9 101 6.4%  4.8 94 4.8% 
Note: a Locus defined as variants within ±1Mb of the lead variant 

















0 17 0%  
9.9´10-6 
0.14 7.2 1.9% 
10% 1 19 5.0%  0.28 8.2 3.3% 






0 14 0%  
1.1´10-5 
0.02 9.2 0.22% 
10% 0 16 0%  0.10 10 0.95% 





0 14 0%  
9.7´10-6 
0.02 7.6 0.26% 
10% 0 16 0%  0.10 8.4 1.2% 






1 170 0.58%  
1.7´10-4 
4.3 218 2.0% 
10% 1 190 0.52%  7.6 241 3.1% 






0 22 0%  
4.0´10-5 
0.62 39 1.6% 
10% 0 22 0%  1.1 47 2.3% 
15% 0 28 0%  1.8 53 3.2% 
Note: a 𝜋!" is the estimated prior probability of association at a variant site equal to the number of loci with 
lead variant P-value less than 5´10-8 divided by 1,000,000 (estimated total number of independent 
common variants in genome). 
b Number of loci in truth set for HDL: 89, LDL: 72, TG: 60, height: 1100, BMI: 724. 
c eFDR is calculated as number of false positives divided by sum of true and false positives. 











Multiple Testing Correction in Rare Variant Analysis 
 
4.1 Introduction 
There is a huge multiple testing burden in genetic association studies which must be addressed to 
control false positive discoveries. This burden was first quantified by Risch and Merikangas (1996) 
for theoretically testing one million alleles and have rapidly increased over time as technological 
and methodological advances allowed us to study a broader range of variants including indels and 
structural variations over a wider allele frequency spectrum. A recent study by the Trans-Omics 
for Precision Medicine (TOPMed) program (Taliun et al., 2019) identified more than 410 million 
genetic variants from 53,581 sequenced individuals. Even after excluding singletons (46%) and 
variants that do not pass quality control filters, there remain more than 120 million variants to be 
tested. 
To account for multiple testing, researchers typically use a genome-wide P-value threshold to 
identify significant associations. For common variant (minor allele frequency [MAF] > 5%) 
studies, this threshold has been set (Dudbridge & Gusnanto, 2008a; Pe’er et al., 2008a) to 5×10-8 
for controlling the family-wise error rate (FWER) at α=5%. Studies including low-frequency 
(MAF 0.5-5%) and rare variants (MAF < 0.5%) have a much greater testing burden than their 
common variant counterparts which necessitates even more stringent P-value thresholds. Recent 
work (D. Lin, 2019; Pulit et al., 2017) has estimated a threshold of approximately 5×10-9 for testing 
~27 million variants from the Haplotype Reference Consortium (HRC) imputation reference panel 
(S. McCarthy et al., 2016). However, this number has already been surpassed by UK Biobank 
(UKBB) studies using the TOPMed reference panel (Taliun et al., 2019) with more than 120 
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million variants available for testing. There is a need to re-estimate the genome-wide significance 
threshold to account for the increased testing burden. 
The Benjamini-Hochberg (Benjamini & Hochberg, 1995) and Benjamini-Yekutieli (Benjamini & 
Yekutieli, 2001a) procedures are alternatives to the P-value threshold and controls the false 
discovery rate (FDR), the expected proportion of false discoveries over a large number of 
hypothetically repeated experiments (Wen, 2016). However, to date, these FDR-controlling 
methods have been only infrequently applied, specifically to association studies limited to common 
and low-frequency variants (Nielsen et al., 2018) or a subset of tests in exome studies (Locke et 
al., 2019). This may be due in part to concerns about FDR control in genetic studies where test 
statistics are strongly correlated due to linkage disequilibrium (LD) between variants, and the 
testing unit and analysis unit may differ (Brzyski et al., 2017; Peterson et al., 2016; Siegmund et 
al., 2011). For example, researchers typically test each variant individually for association with a 
trait but interpret the association results in groups of correlated variants known as loci. Although 
BH and BY control the “global” FDR among all tested variants, this control does not extend to a 
subset of the testing unit such as lead variants from loci (Goeman & Solari, 2014). Modified 
versions of the BH and BY procedures for genetic studies have been proposed (Brzyski et al., 
2017) but their implementation depends on accurately modeling the LD structure among tested 
variants which can be challenging to estimate for rare variants. 
Although BH, BY, and P-value thresholds control different error rates, they act on the same set of 
P-values from association results. Developing a Bayesian method for multiple testing correction 
offers a different approach based on analyzing posterior probabilities instead of P-values. A 
Bayesian method controls the Bayesian FDR, the proportion of false positives among all 
discoveries conditional on the observed data (Wen, 2016; Whittemore, 2007). Several methods 
(Bogdan et al., 2008; Y. Tang et al., 2007; Wakefield, 2007b) have been proposed with differing 
levels of complexity to arrive at the same end goal of calculating the posterior probabilities. Two 
such methods (Bogdan et al., 2008; Y. Tang et al., 2007) formulate a Dirichlet mixture framework 
for modeling the P-value distribution under the alternative hypothesis and estimate the posterior 
probabilities using a Markov chain Monte Carlo (MCMC) algorithm. However, these Bayesian 
methods were developed for quantitative trait loci (QTL) studies involving several hundred 
simultaneous tests and may not scale to testing tens or hundreds of millions of variants in rare 
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variant GWAS. This is an issue because an important advantage of a Bayesian method is that it 
can incorporate prior knowledge about the effect size distribution of the tested variants to improve 
discovery which is especially useful for rare variants that may have large effect sizes but for which 
statistical power for association is still small due to low MAF. Wakefield (2007b) proposed a less 
computationally-intensive method to calculate the posterior probability by combining an 
approximation of the Bayes factor using observed test statistics and user-specified prior 
parameters. The challenge with using this method is that misspecification of the prior can impact 
properties of the Bayesian FDR. 
In this study, we propose a Bayesian method to correct for multiple testing in rare variant studies 
that calculates posterior probabilities using an approximation of the Bayes factor and estimates 
prior parameters from observed summary statistics using an E-M algorithm. An important 
advantage of our Bayesian method is that it only requires GWAS summary statistics (P-values and 
MAF) and so does not require access to individual-level data. We compare the ability of our 
Bayesian method to accurately identify true positives with that of the P-value threshold, BH, and 
BY procedures in simulated datasets based on empirical association structures observed for three 
traits (waist-hip-ratio (WHR), body-mass-index (BMI) , and high-density lipoprotein (HDL) 
cholesterol levels) in the latest genome sequence datasets from the UKBB imputed using TOPMed 
imputation reference panel. In addition, we assess FDR control for our Bayesian method, BH, and 
BY procedures. Finally, we extend the multiple testing methods to gene-based tests and apply them 
to real datasets from the UKBB. 
4.2 Methods 
Consider an additive genetic model for a single continuous trait Y and the genotype Gj at autosomal 
variant 𝑗 = 1,… ,𝑚: 
 𝑌 = 𝑋$𝜃 + 𝐺%𝛽% + 𝜀% (1) 
 where 𝑋 is a p ´ 1 vector of covariates including the intercept, 𝜃 is a p ´ 1 vector of covariate 
effects, 𝛽% is the effect of variant 𝑗, and 𝜀% is the normally distributed error with mean 0 and variance 𝜎%#. 
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For single-variant analysis, we wish to test the null hypotheses 𝐻&,%: 𝛽% = 0 against the alternatives 𝐻",%: 𝛽% ≠ 0 for each variant 𝑗. After applying multiple testing correction, we declare 𝑅 variants to 
be statistically significant. Of these 𝑅 discoveries, 𝑉 of them are false positives and 𝑆 of them are 
true positives. The goal of multiple testing methods is to facilitate the discovery of true positives 
while controlling the number of false positives. 
4.2.1 FWER control 
One way to control false positives in association tests is through the family-wise error rate 
(FWER): 𝐹𝑊𝐸𝑅 = P(𝑉 > 0) 
which denotes the probability of discovering at least one false positive. FWER is typically 
controlled by P-value thresholds using the Bonferroni procedure or modifications that seek to 
account for dependence of the tests. In a set of null hypotheses 𝐻&,% for variants 𝑗 = 1,… ,𝑚, we 
declare variants with P-values less than the threshold 𝛼/𝑚 to be significant, where 𝛼 is the 
acceptable FWER. When variants are in linkage disequilibrium (LD), the corresponding test 
statistics are correlated and the Bonferroni procedure is conservative. Here, one can increase the 
power by adjusting for the effective number of independent tests 𝑚′ instead of 𝑚 (Altshuler et al., 
2005; Dudbridge & Gusnanto, 2008a; Pe’er et al., 2008a). 
4.2.2 FDR control 
An alternative way to control false positives is through the false discovery rate (FDR): 
𝐹𝐷𝑅 = 𝐸 W𝑉𝑅X 
which is the expected proportion of incorrectly rejected true null hypotheses. When the number of 
causal variants 𝑚" = 0, FDR and FWER are identical (Benjamini & Hochberg, 1995). When 𝑚" > 0, FDR is less conservative than FWER at equivalent 𝛼. This implies that every FWER-
controlling method such as the P-value threshold also controls the FDR at that same level (Goeman 
& Solari, 2014). 
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The Benjamini-Hochberg (BH) procedure (Benjamini & Hochberg, 1995) controls the FDR at 
level 𝛼 by ordering the P-values for tested variants from smallest to largest: 𝑝("), … , 𝑝(*) and 
rejecting all null hypotheses 𝐻&,%, 𝑗 = 1,… , 𝑘 where k is the largest value for which 
𝑝(+) ≤ 𝑘𝑚𝛼 
This procedure requires an assumption of positive regression dependence on a subset (PRDS) 
among the test statistics (Benjamini & Yekutieli, 2001a; Goeman & Solari, 2014). In this context, 
this means that variants with more significant (i.e. smaller) P-values need to have a higher 
probability of being a true causal variant than variants with less significant P-values. To control 
the FDR under any arbitrary dependency structure of the test statistics, one can use the Benjamini-
Yekutieli (BY) procedure (Benjamini & Yekutieli, 2001a). This procedure is similar to BH except 
we increase the stringency of our rejection threshold by a factor of 𝑐(𝑚): 
𝑝(+) ≤ 𝑘𝑚: 𝛼𝑐(𝑚); 
 where 
𝑐(𝑚) = ] 1𝑖*,	.	"  
BH is a special case of BY where 𝑐(𝑚) = 1. 
In genetic studies, we typically test each of the 𝑚 variants individually but count the discoveries 
in units of loci (clusters of nearby variants that are correlated due to LD). This has important 
implications for BH and BY because FDR lacks a subsetting property (Goeman & Solari, 2014), 
meaning that FDR-controlling procedures only guarantees control for the set of 𝑅 discoveries from 𝑚 tests but not for any subset of 𝑅. Consider a scenario where a researcher applies BH or BY to 
their association results at an α=5%. The researcher is not interested in controlling the expected 
proportion of false positives in their single-variant discoveries at 5% (because many of these 
discoveries are in LD) but instead is interested in controlling the proportion of falsely discovered 
loci at 5%. In this scenario, the classic BH and BY procedures do not provide the type of FDR-
control that the researcher desire. To address this issue, Brzyski et al. (Brzyski et al., 2017) 
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proposed a modified version of the BH procedure called BHS which adds an initial screening step 
that filters the 𝑚 tested variants into 𝑚∗ < 𝑚 loci before applying the classic BH procedure on the 
lead variant from each locus. Here, the testing and discovery units are both counted in terms of 
loci. 
4.2.3 Bayesian FDR control 
A Bayesian approach to multiple testing correction seeks to control the Bayesian FDR 
(Whittemore, 2007) using posterior probabilities of the null hypotheses given the observed data 𝐷 = ^𝑌, 𝑋, 𝐺%_. Bayesian FDR is the expected proportion of false positives among all discoveries 
conditional on the observed data while the traditional FDR is the average Bayesian FDR over many 
hypothetically repeated experiments (Wen, 2016). 
For a single variant 𝑗, let the probability of the observed data 𝐷 given the null hypothesis	𝐻&,% be P^𝐷`𝐻&,%_. Then by Bayes’ theorem, the probability of the null hypothesis given the data is 
P^	𝐻&,%`	𝐷_ = P^𝐷`𝐻&,%_P^𝐻&,%_P^𝐷`𝐻&,%_P^𝐻&,%_ + P^𝐷`𝐻",%_ a1 − P^𝐻&,%_b = 𝐵𝐹 × 𝑃𝑂𝐵𝐹 × 𝑃𝑂 + 1 
where 𝐵𝐹 = 𝑃^𝐷`𝐻&,%_/𝑃^𝐷`𝐻",%_ is the Bayes factor and 𝑃𝑂 = P^𝐻&,%_/ a1 − P^𝐻&,%_b is the 
prior odds of no association. For quantitative traits, previous work (Servin & Stephens, 2007) has 
derived an exact calculation of the BF: 
𝐵𝐹 = (𝑛)&.A𝑊%&.A 𝑑𝑒𝑡^𝛺%_&.A 𝑌$𝑌 − 𝑌$𝐺/𝛺%!"𝐺/ $𝑌𝑌$𝑌 − 𝑛𝑌# 
!B#
 
where 𝐺/  is a n x 2 matrix with first column all 1s and second column genotype dosages, 𝑊% is the 
prior variance of variant effect, and 𝛺% = a0 00 𝛼b + 𝐺/ $𝐺/ . However, this exact calculation of BF 
requires individual-level data which are frequently unavailable due to data use restrictions. Several 
methods (Bogdan et al., 2008; Y. Tang et al., 2007) have been proposed to estimate the posterior 
probability using a MCMC algorithm but such approach does not scale to rare variant GWAS with 
tens to hundreds of millions of tests. A less computationally-intensive calculation of the BF that 
only requires summary statistics is the approximate Bayes factor (ABF) based on the maximum 
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likelihood estimator of the variant effect 𝛽 as a succinct summary of the observed data 𝐷 
(Wakefield, 2007a): 
 𝐴𝐵𝐹^𝑍% ,𝑊%_ = 5𝑉% +𝑊%𝑉% exp 9−𝑍%#2  𝑊%𝑉% +𝑊%< (2) 
where 𝑍% is the test statistic and 𝑉% is test variance.  
To control (Müller et al., 2004) the Bayesian FDR at level 𝛼, we order the posterior probabilities P(𝐷|𝐻&)	 (abbr. 𝑃𝑃) for the 𝑚 tested variants from smallest to largest: 𝑃𝑃("), … , 𝑃𝑃(*) and declare 𝑅 variants to be significant where 𝑅 is the largest value for which: ∑ 𝑃𝑃(,)	C,	.	"𝑅 ≤ 𝛼 
This is equivalent to saying that we want to discover the largest number of variants such that the 
average posterior probability of the discoveries is less than or equal to 𝛼. 
Calculating the posterior probability for a variant 𝑗 requires two prior parameters: (1) P(𝐻&, 𝑗) =𝜋%, the prior probability of no association and (2) 𝑊%, the prior variance of variant effect 𝛽%. 
Previous work has suggested assigning a fixed or range (Wakefield, 2007a) of values to the prior 
parameters. However, this can be rather arbitrary and may be prone to misspecification, 
particularly in the case of a single value. In this study, we take an empirical Bayes approach to 
estimate the prior parameters from observed summary statistics using an Expectation-
Maximization (E-M) algorithm as described below. 
4.2.4 Prior distribution for effect size 
First, we assume a prior distribution for the effect sizes of our tested variants that follows a mixture 
of three zero-mean normal distributions with a point mass at zero: 
 𝛽%~𝜋&𝛿& + 𝜋"𝑁(0,𝑊") + 𝜋#𝑁(0,𝑊#) + 𝜋<𝑁(0,𝑊<) (3) 
Each variant 𝑗 has probability 𝜋& of being null (i.e. 𝐻% = 0) with an effect size of 0 (denoted by 𝛿&, a point mass at 0) and a probability 𝜋+ of being in one of the non-null groups 𝑘 = 1, 2, or 3 
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with effect size from a 𝑁(0,𝑊+) distribution, where 𝜋& + 𝜋" + 𝜋# + 𝜋< = 1. Under this model, 
variants from the same group 𝑘 will share the same prior parameters 𝜋+ and 𝑊+. 
We chose to model the causal variants using a mixture of three normal distributions because it has 
been shown (Park et al., 2010; Zhang et al., 2018) that any single parametric distribution (e.g. 
normal) does not adequately model the long tails typically present in the effect size distribution of 
complex traits. These tails are the result of rare causal variants that have on average larger effect 
sizes than those of common and low-frequency variants. We treat the membership of each tested 
variant in one of the null or non-null groups as latent variables whose expectations are maximized 
in the E-M algorithm described in the next section. We show later in Results our rationale for 
choosing three non-null groups and how they correspond to MAF bins for common+low-frequency 
(MAF > 0.5%), rare (MAF 0.005-0.5%), and very rare (MAF < 0.005%) variants. 
4.2.5 E-M algorithm 
The goal of our E-M algorithm is to estimate the unknown parameters 𝝅 = {𝜋", … , 𝜋<} and 𝑾 ={𝑊", … ,𝑊<} from the observed summary statistics which is composed of: (1) test statistics Z = {𝑍", … , 𝑍*}, (2) estimated effect sizes 𝜷g = 𝛽", … , 𝛽*, and (3) testing variances 𝑽 = {𝑉", … , 𝑉*}. 
If necessary, we can estimate the effect size and testing variance for each variant from its test 
statistic and MAF (Zhu et al., 2016a). The latent variables are indicators 𝐶%+ for variants 𝑗 =1,… ,𝑚 and for membership in groups 𝑘 = 1,2,3. 
For the E-step, we update the probabilities 𝐶%+(,) for each variant and MAF group: 
𝐶%+(,) = 𝐸𝐶%+𝑍% , 𝜋+(,),𝑊+(,) = 𝜋+(,)𝐴𝐵𝐹a𝑍% ,𝑊+(,)b𝜋&(,) + ∑ 𝜋>(,)𝐴𝐵𝐹a𝑍% ,𝑊>(,)bD>."  
where the formula for ABF is from (2). 
For the M-step, we update the prior probabilities 𝜋+(,) and prior variances 𝑊+(,): 
𝜋+(,E") = 1𝑚]𝐶%+(,)*%."  
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𝑊+(,E") = ∑ 𝐶%+(,)*%." ^𝛽%_#∑ 𝐶%+(,)*%."  
In practice, we found this version of the E-M algorithm tended to overestimate the 𝜋+’s, the prior 
probabilities of association. To address this issue, we modified the update formula for the prior 
probabilities 𝜋+(,) by adding a shrinkage estimator 𝐼a𝐶%+(,) > 𝑡+(,)b where 𝑡+(,) is the median of 𝐶"+(,), … , 𝐶*+(,) . This estimator ensures that we are only counting likely causal variants in the 
estimation of 𝜋+ by “shrinking” very small values of membership probabilities (𝐶%+(,)) belonging to 
non-causal variants to 0. The update formula for 𝜋+(,) in the 𝑖4F M-step of the modified E-M is: 
𝜋+(,E") = 1𝑚]𝐶%+(,)*%." 𝐼a𝐶%+(,) > 𝑡+(,)b 
4.2.6 Empirical analyses 
We applied our Bayesian method, BH, BY, and the P-value threshold to whole-genome sequence 
datasets from the UKBB with genotypes imputed using TOPMed reference panel for analysis of 
three quantitative traits: waist-hip-ratio (WHR), body-mass-index (BMI), and high-density 
lipoprotein (HDL) cholesterol levels. 
We conducted single-variant association testes between each trait and ~107 million variants (9.7 
common, 41 rare, and 57 very rare) found in the TOPMed-imputed genotypes with imputation 𝑅# > 0.1 and minor allele count (MAC) ≥ 3. Analyses were run using linear mixed models 
implemented by SAIGE (W. Zhou et al., 2018). We then ran conditional analysis on the association 
results with P-value < 5×10-8 using GCTA (J. Yang et al., 2011) to obtain sets of near-independent, 
significant variants. 
Our empirical analyses served to demonstrate the performance of multiple testing methods in 




To evaluate the ability of our Bayesian method to identify true positive discoveries and compare 
it with the other multiple testing methods, we simulated 20 replicates for each of the traits WHR, 
BMI, and HDL based on their empirical association structures observed in our empirical analyses. 
For each trait, we generate phenotypes for n individuals according to the following model: 
 𝒀𝒊 = ]𝑿𝒋𝜷𝒋𝑳𝒋.𝟏 + 𝜺𝒊 (4) 
for 𝑖 = 1, . . , 𝑛. Here, 𝑋% is the genotype dosage for the 𝑗4F causal variant obtained from UKBB 
TOPMed-imputed genotypes, 𝛽% is the effect size for the 𝑗4F causal variant obtained from 
conditional analysis, and 𝜀,~𝑁(0, 𝜏) where 𝜏 is the proportion of phenotypic variance not 
explained by the causal variants. For each replicate dataset, we ran single-variant association tests 
using SAIGE. 
4.2.8 Defining true and false positives in simulation 
After applying the multiple testing methods to association results in each replicate dataset, we need 
to know how many of the discoveries made by each method were true and false positives. This 
process is complicated by the fact that not only do causal variants show up as significant 
discoveries in our replicate dataset but also variants in LD with them. To distinguish between true 
and false positives, we create 99% credible sets (The Wellcome Trust Case Control Consortium et 
al., 2012) for each variant discovery to capture the causal variant responsible for that signal. 
Consider a set of 𝑅 variants declared significant by a given multiple testing method (e.g. P-value 
threshold). For each variant 𝑗 = 1,… , 𝑅, we cluster together all other tested variants within ±1Mb 
of variant 𝑗. Within each cluster, we calculate the posterior probability for each of the 𝑚% variants 
in the cluster as: 
𝑝𝑝, = 𝐴𝐵𝐹,∑ 𝐴𝐵𝐹,*",."  
where ABF is calculated using (2). We then form a 99% credible set for variant 𝑗 as the smallest 
set of variants from the cluster such that 99% of the posterior probability is accounted for. If the 
credible set for variant 𝑗 contains a causal variant or a variant with LD 𝑟# > 0.80 with a causal 
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variant, we consider variant 𝑗 to be a true positive. Conversely, if neither of those two criteria are 
met, then we consider variant 𝑗 to be a false positive. 
4.2.9 Gene-based tests 
Single-variant tests often lack power to detect rare variant associations due to their low allele 
frequencies (Asimit & Zeggini, 2010) and massive testing burden which requires a stringent 
significance threshold (Seunggeung Lee et al., 2014). An alternative to testing each variant 
individually is to combine the effects of multiple variants within a gene or region and test for 
association between this cumulative effect and a trait of interest. Compared with single-variant 
tests, these gene- or region-based tests have a smaller testing burden and are more powerful if 
multiple variants within the gene or region are associated with the trait (Seunggeung Lee et al., 
2014). In this section, we describe the extension of the multiple testing methods specifically for 
gene-based tests, but these methods will be equally applicable to the more general region-based 
tests. 
Suppose that the 𝑚 variants from model (1) are from a single gene 𝛾. For the burden test (Asimit 
& Zeggini, 2010; B. Li & Leal, 2008), we aggregate all 𝑚 variants into a single genetic score: 
𝐶K =]𝑤,𝐺,*,."  
using weights (𝑤,) based on MAF and the genotype dosage (𝐺,). We can then test for association 
between the aggregate score and a trait. This is equivalent to testing a single null hypothesis 𝐻&: 𝛽 = 0 in (1) for no association between the aggregate score and the trait using the score 
statistic: 
𝑄L=MN3B = :] 𝑤,𝑆,*#,." ;# 
where 𝑆, is the score statistic from single-variant analysis. 
For the sequence kernel association test (SKAT) (Wu et al., 2011), we assume that 𝛽% from (1) 
comes from a distribution with mean 0 and variance 𝑤%#𝜏 and test the single null hypothesis 𝐻&: 𝜏 =0 using a variance component score test: 
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𝑄OD7$ =] 𝑤,#𝑆,#*#,."  
The burden test is more powerful than SKAT if the gene contains a high proportion of causal 
variants with the same direction of effects while SKAT is more powerful if there is a sizeable 
number of noncausal variants in the gene or if the causal variants have different direction of effects 
(Seunggeung Lee et al., 2014). SKAT-O (Seunggeun Lee et al., 2012) is an omnibus tests that 
seeks to maximize power across both scenarios by optimally combing the burden and SKAT test 
using an adaptive procedure based on the observed data. 
4.2.10 Multiple testing for gene-based tests 
Typically, we would conduct a set of gene-based tests for each of the 𝐿 genes in our dataset. Here, 
we need to correct for multiple testing just like we did for single-variant tests. 
To control FWER in the set of 𝐿 genes at level α, we use the Bonferroni procedure and declare 
genes with P-values less than 𝛼/𝐿 to be significant. Similar to single-variant tests, we can increase 
power by adjusting for the effective number of independent tests 𝐿′ instead of 𝐿. However, past 
work (D. Lin, 2019) has found only a slight difference between these two number of tests, likely 
due to weak LD among rare variants and across genes. Thus, it may be preferable to use the total 
number of genes 𝐿 in the Bonferroni procedure to avoid the computation cost and limited gain 
from estimating the number of independent tests 𝐿′. 
To control FDR among the tested genes, we directly apply the BH and BY procedure described in 
section 4.2.2 to the P-values from gene-based tests. Since both our testing and analysis are 
conducted in units of genes, we do not need to apply the modifications proposed by Brzyski et al. 
(Brzyski et al., 2017) as we did for single-variant testing. 
Extending our Bayesian method to gene-based tests, we calculate a gene-level BF (Wilson et al., 
2010) to test the null hypothesis of no association between any variants in gene 𝛾 and the trait 
versus the alternative hypothesis of at least one association. The gene-level BF is: 
𝐵𝐹K = 1𝑚]𝐵𝐹%*%."  
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where the 𝐵𝐹% can be approximated using equation (2) in the absence of individual-level data. To 
simplify calculations, we make the exchangeability assumption that every tested gene has the same 
prior probability 𝜋K of being associated with the trait and then conservatively estimate 𝜋K as the 
proportion of tested genes with P-values less than 𝛼/𝐿. This assumption can be relaxed, allowing 
for different priors among tested genes based on the functional annotations of variants within the 
genes (H. Yang & Wang, 2015). We then calculate the posterior probability of association for each 
of the tested genes and control the Bayesian FDR using the procedure described in section 4.2.3.   
4.3 Results 
4.3.1 Null simulations 
To estimate the genome-wide significant P-value threshold for rare variant studies, we simulated 
association results under the global null hypothesis of no association to any genetic variant using 
genotypes for ~107 million variants from the n=487,409 individuals in the TOPMed-imputed 
UKBB dataset and phenotypes randomly generated from a standard normal distribution 
independent of genotypes. Figure 4.1 shows the distribution of minimum P-values from 100 
genome-wide simulations partitioned by MAF. The 5% quantile of the minimum P-values for each 




Figure 4.1: Minimum P-value distribution 
 
Minimum P-value distribution for 100 simulations under the global null hypothesis. Horizontal dotted 
lines represent the 5% quantile of minimum P-values in each MAF bin. Rare: MAF≤0.5%, Common+LF: 
MAF>0.5%, Common: MAF>5%. 
 
We estimated a P-value threshold of 9.3×10-10 for testing ~107 million total variants with minor 
allele count (MAC) ≥ 3 in our dataset (Supplementary Table 4.1). This is equivalent to testing 53.7 
million independent variants (0.05/9.3×10-10). We also estimated a threshold of 8.2×10-9 to test 9.7 
million common (MAF > 5%) and low-frequency variants (MAF 0.5-5%), 9.6×10-9 to test 3.8 
million low-frequency (LF) variants, and 4.6×10-8 to test 5.9 million common variants. 
Interestingly, our estimated threshold to test 98 million rare (MAF < 0.5%) variants was the same 
as our estimated threshold to test all 107 million variants. This is partly due to a lack of precision 
in the estimates arising from only simulating 100 null replicates but also is consistent with the fact 
that the vast majority of the testing burden can be attributed to rare variants. 
4.3.2 Non-null simulations 
We generated three sets of 20 simulation replicates using model (2) to assess the true and false 
positive rate of the multiple testing methods. Table 4.1 summarizes the empirical association 
results for the three traits on which we based our three sets of simulation: waist-hip-ratio-based 
(WHRsim), body-mass-index-based (BMIsim), and high-density lipoprotein cholesterol levels-based 
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(HDLsim). For each trait we used the conditionally independent variants with MAC ≥ 3 and 
conditional P-value < 5×10-8 as causal variants in our simulation models. 
Table 4.1: Description of empirical datasets and association results used to inform simulations 
Trait Sample size MAF bin 







Common+LF (>0.5%) 9.7 179 
 Rare (0.005-0.5%) 41 20 
 Very rare (<0.005%) 57 40 
BMIsim 
406,860 
Common+LF (>0.5%) 9.7 313 
 Rare (0.005-0.5%) 41 26 
 Very rare (<0.005%) 57 0 
HDLsim 
356,103 
Common+LF (>0.5%) 9.7 384 
 Rare (0.005-0.5%) 41 120 
 Very rare (<0.005%) 55 0 
1Variants with conditional P-values<5×10-8 
The simulated traits have different genetic architectures with WHRsim having the fewest causal 
variants (239) and HDLsim having the most (504). In addition, WHRsim is the only simulated trait 
with causal variants that have MAF < 0.005%.  
In the effect size distribution of causal variants for BMIsim and HDLsim (Supplementary Figure 
4.1D and 4.1F) we observe that the effect sizes for causal rare variants (blue) are noticeably 
elevated compared to the effect sizes of causal common+LF variants (red). However, we observe 
in WHRsim (Supplementary Figure 4.1B) the presence of very rare (MAF < 0.005%) variants 
(purple) which have much larger effect sizes than the detected rare and common+LF variants. We 
believe these very rare causal variants should be modeled differently than rare or common+LF 
variants, hence the mixture of three normal distributions. We observe in the application of our EM 
algorithm for all three traits that membership into the non-null groups among the tested variants 
with small (i.e. significant) P-values is largely in accordance with MAF (Supplementary Figure 
4.2). Almost all of the common variants are placed into group 𝑘 = 1 with a small estimated prior 
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variance while rare and very rare variants are placed into groups 𝑘 = 2 and 𝑘 = 3 with larger prior 
variances. 
4.3.3 True and false positive rate of multiple testing methods 
We compared the abilities of the four multiple testing methods: P-value threshold, BH, BY, and 
our proposed Bayesian method to accurately classify true and false positive variants in our three 
sets of simulations. We divide the four methods into two categories: (1) methods that classify true 
and false positives using posterior probabilities and (2) methods that classify true and false 
positives using P-values. Our Bayesian method falls into the first category while the other three 
methods fall into the second. Since methods within each category produce identical true positive 
rates (TPR) at the same false positive rate (FPR), we only present results for our Bayesian method 
and the P-value threshold. 
Figure 4.2: Classifying true and false positive variants 
 
Receiver operating characteristic (ROC) curves for the Bayesian method and P-value threshold in (A-C) 
all variants and (D-F) rare+very rare variants (MAF<0.5%) in our simulated datasets based on the waist-
hip-ratio (WHR), body-mass-index (BMI), and high-density lipoprotein (HDL) cholesterol level traits. 
 
Figure 4.2 shows the receiver operating characteristic (ROC) curves for our Bayesian method and 
P-value-based methods. For variants across the full allele frequency spectrum in all three sets of 
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simulations, our Bayesian method identifies more true positives than the P-value threshold at the 
same false positive rates (Figure 4.2A-C). We can quantify this difference using the area-under-
curve (AUC), a measure of discriminatory power. The average AUC for our Bayesian method in 
WHRsim is 93% compared with 87% for the P-value threshold (Table 4.2). We see a similar pattern 
for the other two simulated traits where the average AUC for our Bayesian method is again 5-7% 
higher than that of the P-value threshold. 
Table 4.2: AUC values for multiple testing methods 
Trait Method 
All variants MAF < 0.5% 
AUC 95% CI AUC 95% CI 
WHRsim P-value 0.866 (0.860, 0.871) 0.713 (0.693, 0.733) 
 Bayesian 0.929 (0.924, 0.934) 0.716 (0.695, 0.738) 
BMIsim P-value 0.892 (0.888, 0.896) 0.666 (0.648, 0.684) 
 Bayesian 0.942 (0.937,0.947) 0.723 (0.709, 0.738) 
HDLsim P-value 0.867 (0.865, 0.870) 0.671 (0.667, 0.674) 
 Bayesian 0.939 (0.938, 0.940) 0.699 (0.694, 0.703) 
 
To investigate this surprisingly large increase in power, we calculated the TPR for both methods 
at an identical FPR of 1% (Supplementary Table 4.2) and found that our Bayesian method has a 
more relaxed threshold for discovery compared to the P-value threshold. For example, in WHRsim, 
the average maximum P-value of the discoveries made by our Bayesian method is 8.1×10-8 
compared with 2.6×10-8 for the P-value threshold. On average, there is a total of 857 variants 
between these two P-values in the simulated replicates for WHRsim and 850 (99%) of them were 
true positives. Thus, our Bayesian method was making more discoveries within a set of variants 
which were almost all true positives, substantially increasing the number of true positives 
identified compared to the P-value threshold which did not consider any of these variants as 
significant discoveries. We saw similar patterns for BMIsim and HDLsim. We continue to explore 
this unexpectedly large difference. 
4.3.4 True and false positive rate of multiple testing methods for rare variants 
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Considering only rare and very rare variants (Figure 4.2D-F), our Bayesian method has 
approximately the same power as the P-value-based methods for WHRsim but greater power for 
BMIsim and HDLsim. This can be seen in the average AUC values for our Bayesian method which 
were similar between the three sets of simulations (70%-72%) while the average AUC for the P-
value threshold dropped from 71% in WHRsim to 67% in BMIsim and HDLsim (Table 4.2). This may 
be due to the larger proportion of rare and very rare false positive variants in the latter two traits. 
Our Bayesian method limited its discovery of these false positives through smaller estimates of 
the prior probabilities for these two MAF bins (Supplementary Table 4.3) but the P-value threshold 
is unable to use information other than the test statistic in classifying (true and false) positives. 
4.3.5 FDR control for all discoveries versus a subset of discoveries 
As described in Methods, it is important to consider the testing unit when assessing FDR control 
for the BH and BY procedures. These procedures are designed to control the “global” FDR among 
all discovered variants but do not guarantee control if the variants are clustered into loci later in 
the analysis. When we wish to control the FDR among loci, it is more appropriate to use the 





Figure 4.3: Control of FDR 
 
Control of FDR among (A-C) all discoveries and (D-F) a subset of all discoveries formed using lead variants 
from discovered loci. For the BH and BY procedures, we show the plot of FDR control in loci for the 
modified version of the methods, BHS and BYS, due to large inflations observed in the classic versions. 
 
Figure 4.3A-C shows the control of global FDR at 1-5% for our Bayesian method, BH, and BY 
procedures. Both our Bayesian method and BY procedure controlled the empirical FDR (eFDR) 
at or below the theoretical FDR threshold for all simulated traits, albeit very conservatively. For 
example, the average eFDR at thresholds 1-5% in WHRsim is 0.064%-0.23% for our Bayesian 
method and 0.13%-0.35% for BY. BH showed slightly inflated eFDR for WHRsim (1.2-5.7%), 
moderately inflated eFDR for BMIsim (2.0-8.2%), and very inflated eFDR for HDLsim (6.0-17%). 
This is likely due to the correlation between test statistics that violates the PRDS assumption. As 
the number of causal variants increase, the number of correlated test statistics also increases, 
resulting in further departure from a positive dependency structure. This likely explains the greater 
inflation for BMIsim and HDLsim than for WHRsim. 
Figure 4.3D-F shows the control of FDR for the lead variants from discovered loci, (a subset of 
the discovered variants. Both our Bayesian method and the modified BY procedure (BYS) control 
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the eFDR in loci at theoretical thresholds 1-5% with a slight inflation at 1% for the Bayesian 
method in all three simulated traits (1.2%, 1.4%, and 1.2%) and for the BYS procedure in HDLsim 
(1.3%). Our Bayesian method’s control of eFDR is much less conservative in loci (Figure 4.3D) 
than in all discovered variants (Figure 4.3A). However, BYS control of eFDR in loci for WHRsim 
and BMIsim remained conservative (Figure 4.3E). The classic BH and BY procedures did not 
control the eFDR in loci at any threshold from 1-5% (Supplementary Figure 4.3), consistent with 
the lack of subsetting property for FDR-controlling procedures. 
4.3.6 Empirical analyses 
To compare the multiple testing methods in real datasets, we applied the P-value threshold, BYS, 
and our Bayesian method to the actual TOPMed-imputed UKBB data for BMI, WHR, and HDL 
(Table 4.1). We excluded BH, BHS, and BY from our empirical analyses because of their poor 
eFDR controls in loci in our simulations. 
To estimate the proportion of true positives among the common+LF discoveries in WHR and BMI, 
we compared our results with those from a meta-analysis (Pulit et al., 2019) of 485,486 individuals 
from the UKBB study and 212,248 individuals from the Genetic Investigation of Anthropometric 
traits (GIANT) consortium (combined n=697,734) on the same traits. We considered any of our 
discoveries that were within the locus (defined as ±1Mb physical distance from the index variant) 
of a genome-wide significant variant (P-value<5×10-8) in the meta-analysis to be true positives. 
Since the UKBB study was used in both our empirical analyses and the meta-analysis, there are 
significant overlaps in samples between the two set of results. However, considering the large 
sample size differences between the two analyses, we believe the meta-analysis can still serve as 
an approximate “truth set” for our empirical results. We were unable to repeat this process for the 




Table 4.3: Empirical results for selected multiple testing methods 
Trait Method Threshold 








WHR P-value P=1×10-9 102 (102) 4 12 
 BYS FDR=2% 117 (115) 6 20 
 Bayesian BFDR=2% 162 (159) 14 45 
BMI P-value P=1×10-9 152 (152) 6 0 
 BYS FDR=2% 196 (195) 7 0 
 Bayesian BFDR=2% 293 (288) 27 0 
HDL P-value P=1×10-9 217 56 0 
 BYS FDR=2% 259 83 0 
 Bayesian BFDR=2% 366 242 0 
1True positives defined as within ±1Mb physical distance from variant with P-value<5×10-8 in truth set 
  
Table 4.3 shows the empirical results with the number of conditionally independent variants 
discovered by each method partitioned by MAF. All conditionally independent common+LF 
discoveries made by the P-value threshold for WHR and BMI were found in the truth set. For the 
BYS procedure, 115 out of 117 (eFDR=1.7%) common+LF discoveries were found in the truth set 
for WHR and 195 of 196 (eFDR=0.5%) for BMI. For the Bayesian method, we observed similar 
levels of eFDR between the two traits for this MAF bin (1.9% for WHR, 1.7% for BMI). 
4.3.7 Results for gene-based tests 
To assess the performance of the multiple testing methods in gene-based tests, we applied the 
methods to whole-exome sequence data on 49,960 individuals from the UKBB (Hout et al., 2019). 
We conducted single-variant and gene-based tests (SKAT-O) on a subset of 36,364 individuals 
from the UKBB whole-exome dataset with phenotype values on the HDL trait. In total, there are 
~5.23 million variants with MAF between 0.0014-1% in the dataset which were grouped into 
17,795 genes. Due to the heavy computation cost, we restricted our analysis to the HDL trait. 
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To correct for multiple testing among the 17.795 tested genes, we used a P-value significance 
threshold of 2.8×10-6 (0.05/17795) and thresholds for BH and the Bayesian method corresponding 
to theoretical FDR of 5%. A Venn diagram of the discoveries for the P-value threshold, BH 
procedure, and Bayesian method can be seen in Figure 4.4. We did not include results for the BY 
procedure because its discoveries were a proper subset of the discoveries made by BH. 
Figure 4.4: Results for gene-based tests 
 
Comparison of discoveries made by different multiples testing methods for gene-based tests. 
In total, there were 13 unique genes declared significant by the three multiple testing methods 
(Figure 4.4). APOC3, TAGLN, and CETP were discovered by all three methods and are protein 
encoding genes that have been found to be associated with HDL in previous studies (Jeong et al., 
2014; Luo et al., 2017; Willer et al., 2013). Comparing the two P-value-based methods, we 
observed that the BH procedure discovered four more genes (ABCA1, ASXL2, GDF1, PLA2G12A) 
than the P-value threshold. ABCA1 is a protein coding gene that has been previously found to be 
associated with lipid metabolism in human subjects (Willer et al., 2008) while the other three genes 
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are potential novel discoveries that have only been previously found to affect lipid metabolism 
(Izawa et al., 2015; Shen et al., 2009) or HDL particle size (Strunz et al., 2020) in mice. Finally, 
the Bayesian method discovered four genes (LCAT, LIPG, MADD, PIGV) that were not discovered 
by the two P-value-based methods, all of which have been previously shown to be associated with 
HDL (Stanley et al., 2017; Willer et al., 2013). 
4.4 Discussion 
In this study, we proposed a Bayesian method that correct for multiple testing in rare variant 
association studies. We assessed the ability of our Bayesian method to discover true positive 
associations while controlling the number of false positives in simulated replicates for three traits 
with different genetic architecture and compared it to using the P-value threshold, and the BH and 
BY procedures. 
4.4.1 Bayesian vs. P-value-based methods for multiple testing 
Our proposed Bayesian method controls the proportion of false positives among all discoveries 
and does not require individual-level nor arbitrary specification of priors. It calculates the posterior 
probabilities using an approximation of the Bayes factor derived from the test statistic and 
estimates the prior parameters from observed association results using an E-M algorithm. Across 
three simulated traits we considered, our Bayesian method better distinguished between true and 
false positives than the three P-value-based methods: the P-value threshold, and the BH and BY 
procedures. On average, the AUC for our Bayesian method was 5-7% higher than that of the P-
value-based methods among all tested variants and 1-5% higher among rare (MAF 0.5-0.005%) 
and very rare (MAF < 0.005%) variants. This is likely because our Bayesian method uses extra 
information about the effect size distribution of tested variants (i.e. prior probabilities of different 
MAF bins) to improve its true positive discovery. This information is accurate because it is 
estimated directly from the data in a principled way. 
4.4.2 FDR control for genetic loci 
In genetic studies, we typically test for association between the trait and each individual variant 
but analyze our results in clusters of correlated variants called loci. This means that FDR-
controlling methods such as the Bayesian method, and the BH and BY procedures need to control 
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the eFDR in both the full set of discovered variants and, more importantly, in a subset composed 
of lead variants from discovered loci. We found that only the Bayesian method and the modified 
BY procedure (BYS) controlled the eFDR in both sets of discoveries at theoretical thresholds of 1-
5% for all three simulated traits; the classic BH, BY, and modified BH (BHS) procedures showed 
inflated eFDR ranging from slight inflation for WHRsim to heavy inflation for HDLsim.  
4.4.3 Stratified FDR method 
There are similarities between our proposed Bayesian method and the stratified FDR procedure 
(Sun et al., 2006) that divides all tested variants into strata and estimate a different proportion of 
null hypothesis (𝜋&) for each stratum. These strata can be defined based on external information 
(e.g. MAF) and the estimated 𝜋&’s are then incorporated into the BH or BY procedure applied 
separately to each stratum. If the 𝜋&’s are truly variable across the different strata, then the stratified 
FDR procedure will have increased power to detect true associations compared with the non-
stratified approach (ChangJiang Xu et al., 2014). However, the stratified FDR procedure is 
designed to control FDR in the set of all discovered variants but does not guarantee the control 
will hold for the subset of discovered loci. As we have shown in our results, this is an important 
property that is required for FDR-controlling procedures in GWAS. It may be possible to modify 
the stratified FDR procedure similar to BHS (Brzyski et al., 2017) but such adjustment is beyond 
the scope of this work.  
4.4.4 Genome-wide significant P-value threshold 
We used null simulations to estimate a genome-wide significant P-value threshold for testing our 
set of ~107 million (98 million with MAF < 0.5%) variants. Although previous work (D. Lin, 
2019; Pulit et al., 2017) have estimated this threshold to be 5×10-9 for testing ~27 million variants 
found in the imputation reference panel from the 1000 Genomes phase 3 study (The 1000 Genomes 
Project Consortium et al., 2015), we have a much larger testing burden in our dataset which 
requires a more stringent threshold. Indeed, we estimated a P-value threshold of 1×10-9 for testing 
107 million variants from the TOPMed imputation reference panel (Taliun et al., 2019), equivalent 
to 53.7 million independent tests. As expected, we found our testing burden to be mainly attributed 
to the large number of rare and very rare variants. 
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In addition, we estimated a P-value threshold of 5×10-8 for testing 5.9 million common variants, 
equivalent to 1.1 million independent tests. Compared with common variants, the smaller 
difference between the total number of tests and estimated number of independent tests for rare 
variants suggests a lower impact of LD on rare variants in our dataset.   
4.4.5 Choosing between multiple testing methods 
In this study, we presented our assessment of four different multiple testing methods for three 
simulated traits. When choosing between the methods, it is important to consider the goal of the 
study. If the goal is to generate a carefully curated list of loci for expensive downstream analyses 
(e.g. building animal models), then the P-value threshold is the most appropriate multiple testing 
method due to its stringent control of even a single false positive discovery. However, if the goal 
is to instead generate a large number of true positive loci for less expensive, high-throughput 
downstream analyses (e.g. high throughput bioinformatics or functional follow-up) while 
controlling the proportion of false discoveries, then FDR-controlling methods may be more 
appropriate. In this case, our Bayesian method using posterior probabilities demonstrated better 
ability to discover true positives than the BH or BY procedures that rely on P-values while also 
controlling the eFDR among discovered loci at FDR thresholds of 1-5%. The Bayesian method 
may be particularly attractive for testing rare variants where there are likely to be a large number 
of true signals but P-value thresholds lack power to detect them due to low allele counts.  
4.4.6 Limitations 
In this study, we did not model the LD between tested variants in our E-M algorithm for the 
Bayesian method. This is due to the heavy computation cost of estimating the LD structure for 
~107 million variants in our dataset. As a results, groups of significant variants correlated with the 
causal variant can inflate the estimated proportion of causal variants for common and low-
frequency variants which will affect the performance of the Bayesian method for those MAF bins. 
This inflation is likely mitigated for rare variants due to weak LD between those variants. An 
alternative to estimating the LD structure is to use a LD-pruned set of independent variants for the 
E-M algorithm. The effect of this choice on the estimated priors for the Bayesian method requires 




We showed that our Bayesian method have more true positive discoveries than other multiple 
testing methods at similar false positive rates while maintaining control of FDR. We estimated a 
genome-wide significant P-value threshold of 1×10-9 to test ~107 million variants from the 
TOPMed imputation panel which is 5× more stringent than the currently used 5×10-9 threshold for 




4.5 Supplementary Figures 
 
Supplementary Figure 4.1: Allele frequency and effect size distributions for empirical dataset 
 
Minor allele frequency (MAF) and effect size distributions for (A-B) waist-hip-ratio, (C-D) body-mass-
index, and (E-F) high-density lipoprotein (HDL) cholesterol levels in real data from the UK Biobank 
study with TOPMed-imputed genotypes. 
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Supplementary Figure 4.2: Non-null group membership for significant variants in simulation 
 
Membership into non-null groups 𝑘 = 1, 2, 3 for significant variants as determined by E-M algorithm for 
simulated traits (A) waist-hip-ratio, (B) body-mass-index, and (c) high-density lipoprotein cholesterol 
levels. Vertical dotted lines denote MAF cutoffs for common+LF (MAF > 0.5%), rare (MAF 0.005-
0.5%), and very rare (MAF < 0.005%) varaints.  
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Supplementary Figure 4.3: Control of eFDR in loci for the classic BH and BY procedures. 
 
Control of eFDR in discovered loci at thresholds 1-5% for simulated traits.  
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4.6 Supplementary Tables 
 
Supplementary Table 4.1: Estimated genome-wide significant P-value thresholds from 100 null 
simulation 
MAF bin PGWS at α=5% 
Total # of 
variants 
(millions) 
Total # of 
independent tests 
(millions) 
All 9.3×10-10 107 53.7 
Rare only (<0.5%) 9.3×10-10 97.7 53.7 
Common+LF(>0.5%) 8.2×10-9 9.68 6.10 
Common only (>5%) 4.6×10-8 5.92 1.09 
 
 
Supplementary Table 4.2: Numbers of true and false positives identified at false positive of 1% 
Trait Method FP TP Max P-value 
Total variants between 
max P-values 
FP TP (%) 
WHRsim P-value 6.2 4822 2.6×10-8 - - 
 Bayesian 6.3 5574 8.1×10-8 6.9 850 (99%) 
BMIsim P-value 10 19823 2.4×10-8 - - 
 Bayesian 11 20897 7.7×10-8 19 2065 (99%) 
HDLsim P-value 32 30080 8.7×10-9 - - 





Supplementary Table 4.3: E-M estimates of prior probabilities for simulated traits 
Trait MAF bin 
E-M estimates of prior 
probability 
(95% CI) 
Conservative1 estimates of 
prior probability 
(95% CI) 
WHRsim Common+LF (>0.5%) 1.7 (1.7-1.8)×10-4 3.3 (3.2-3.4)×10-5 
 Rare (0.005-0.5%) 0.99 (0.69-1.3)×10-6 7.5 (5.4-9.6)×10-8 
 Very rare (<0.005%) 0.95 (0.75-1.2) ×10-6 3.0 (2.1-3.8) ×10-7 
BMIsim Common+LF (>0.5%) 6.6 (6.5-6.7) ×10-4 1.5 (1.5-1.5) ×10-4 
 Rare (0.005-0.5%) 1.7 (1.6-1.9) ×10-5 7.2 (5.6-8.8) ×10-7 
 Very rare (<0.005%) 0.91 (0-2.7) ×10-9 1.4 (0-2.9) ×10-9 
HDLsim Common+LF (>0.5%) 5.5 (5.4-5.6) ×10-4 2.3 (2.3-2.3) ×10-4 
 Rare (0.005-0.5%) 1.9 (1.9-2.0) ×10-4 1.9 (1.9-1.9) ×10-5 
 Very rare (<0.005%) 3.2 (2.7-3.7) ×10-7 6.5 (6.0-7.0) ×10-7 














In this dissertation, I provided recommendations on aggregating sequence data from multiple 
studies, assessed the performance of different multiple testing methods in common variant GWAS 
leveraging sequential meta-analyses to approximate a truth set, and developed a Bayesian method 
for multiple testing correction in rare variant studies. Here, I review these projects, discuss their 
limitations, and provide directions for future research. 
5.2 Viability of single-study variant calling strategy for rare variants 
In Chapter 2, we compared the gold standard joint variant calling strategy to the more 
computationally efficient single-study strategy in terms of variant detection, genotype accuracy, 
and power of downstream association analyses. Due to computation time and burden, we limited 
our study to variants in chromosome 2. Additional variants from analyzing more chromosomes 
would be helpful in comparing association power between joint and single-study strategies for 
genome-wide significant (P-value<5x10-8) rare variants. Currently, our single-variant and gene-
based analysis of rare variants are centered on those with P-values≥5x10-5 with limited information 
on rare variants near the genome-wide significance threshold. Further analyses in sequence studies 
with larger sample sizes can reveal whether the single-study strategy maintains similar power to 




5.3 Evaluation of multiple testing methods in real datasets 
In Chapter 3, we assessed the performance of the several multiple testing methods in terms of true 
and false positive discovery for array-based common variant GWAS. In our empirical analyses, 
we defined true and false positive discoveries using the largest, most recent common variant 
GWAS which we called the truth sets. Although this did not guarantee the (unknown) list of loci 
truly associated with each tested trait, the truth sets served as reasonable approximations when 
there were considerable sample size differences between the truth and test sets. However, some 
bias likely remains in our analysis due to sample overlap between our truth and test sets. This can 
be mitigated in future analyses by using truth sets from independent studies on the same traits. 
Our empirical analyses in Chapter 3 serves as a template for assessing multiple testing methods in 
an applied real-data setting. Although we conducted extension simulation in Chapter 4, we were 
unable to verify the performance of our Bayesian method (as well as the other multiple testing 
methods) for rare variants in an applied setting due to a lack of truth sets for the TOPMed-imputed 
UKBB datasets. Ongoing projects by the Global Lipids Genetic Consortium (GLGC) to study 
variant associations with blood lipid levels in whole-genomes sequencing and large imputation-
based cohorts serve as useful truth sets for our high-density lipoprotein (HDL) cholesterol level 
trait. 
5.4 Alternative models for effect size distribution 
In Chapter 4, we proposed a Bayesian method for multiple testing that estimated the prior 
parameters from summary statistics using an E-M algorithm. A key component of this method is 
accurately modeling the true effect size distribution of our tested variants. There has been extensive 
work in this area for polygenic risk prediction models (Chatterjee et al., 2016) that assume the true 
effect size distribution is a mixture of normal distributions with (Guan & Stephens, 2011; Moser 
et al., 2015) and without (X. Zhou et al., 2013) a point mass at 0, a double exponential distribution 
(Yi & Xu, 2008), or generalization to a normal exponential gamma distribution (Hoggart et al., 
2008). In addition, GENESIS (Zhang et al., 2018) is a publicly available software that estimates 
the effect size distribution from GWAS summary statistics. This approach is similar to our E-M 




For our Bayesian method, we chose a mixture model of three normal distributions along with a 
point mass at 0 to represent the observed effect size distribution in our empirical analyses where 
the magnitude of effect differed for three distinct groups based on MAF: common (MAF>5%) and 
low-frequency (MAF 0.5-5%), rare (MAF 0.005-0.5%), and very rare (MAF<0.005%) variants. 
In addition, the choice of normal distributions aligns well with the approximate Bayes factor 
(Wakefield, 2007a) used in our method and simplifies calculation of the prior variance of variant 
effect. Although our Bayesian method showed strong performances using the selected model, there 
needs to be consideration of alternative models with different numbers of MAF bins and different 
types of distributions. The goal is for the E-M algorithm to accurately estimate the prior parameters 
across traits with different levels of polygenicity. We plan to compare the performance of our 
Bayesian method for different prior effect size models in both simulated and empirical datasets. 
5.5 Closing remarks 
Genetic association studies are the first step in the long journey from discovering associated 
variants or loci to identifying potentially causal genes and finally to understanding the biological 
mechanism or pathway in which genetics affect diseases or traits. At a time when new sequencing 
technology and larger imputation panels allow us unprecedented access to rare variant genotypes, 
we must balance the need to limit costly false discoveries with the need to promote true discoveries 
in order to better understand our genetic makeup. To do this, we must continue to develop new 
statistical methods and update existing ones to deal with the challenges in analyzing a rapidly 
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